

1. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterol* 1995; 108: 417-422.
2. Aghdassi E, Carrier J, Cullen J, Tischler M, Allard JP. Effect of iron supplementation on oxidative stress and intestinal inflammation in rats with acute colitis. *Dig Dis Sci*. 2001 46: 1088-94.
3. Agret, F, Cosnes, J, Hassani, Z, Gornet, J. M, Gendre, J. P, Lemann, M, and Beaugerie, L. Impact of pregnancy on the clinical activity of Crohn's disease. *Aliment.Pharmacol.Ther.* 2005; 21: 509-13.
4. Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. *Gut* 2005; 54: 257-63.
5. Alabaz O, Iroatulam AJ, Nessim A, et al. Comparison of laparoscopically assisted and conventional ileocolic resection for Crohn's disease. *Eur J Surg* 2000; 166: 213-217.
6. Albersnagel FA, Dijkstra G Inflammatoire darmziekten. *Medische en psychologische aspecten. Tijdschrift Psychologie en Gezondheid*, 2007; 35: 24-35.
7. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. *Gut* 2005; 54: 1721-7.
8. Alcantara M, Rodriguez R, Potenciano JL, Carrobes JL, Gomez R. Endoscopic and bioptic findings in the upper gastrointestinal tract in patients with Crohn's disease. *Endoscopy*. 1993; 25: 282-6.
9. Allan A, Andrews H, Hilton CJ, et al. Segmental colonic resection is an appropriate operation for short skip lesions due to Crohn's disease in the colon. *World J Surg* 1989; 13: 611-4; discussion 615-6.
10. Allen J, Hector, D. Benefits of breastfeeding. *N.S.W.Public Health Bull.* 2005; 16: 42-6.
11. Alstead, E. M. and Nelson-Piercy, C. Inflammatory bowel disease in pregnancy. *Gut* 2003; 52: 159-61.
12. Alstead, E. M, Ritchie, J. K, Lennard-Jones, J. E, Farthing, M. J, Clark, M. L. Safety of azathioprine in pregnancy in inflammatory bowel disease. *Gastroenterol* 1990; 99: 443-6.
13. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. *Am J Gastroenterol* 2000; 95: 3418-22.
14. Andersson H, Bosaeus I, Fasth S, Hellberg R, Hulten L. Cholelithiasis and urolithiasis in Crohn's disease. *Scand J Gastroenterol* 1987; 22: 253-256.
15. Andersson P, Olaison G, Hallbook O, Sjordahl R. Segmental resection or subtotal colectomy in Crohn's colitis? *Dis Colon Rectum* 2002; 45: 47-53.
16. Andreoli A, Cerro P, Falasco G, Giglio LA, Prantera C. Role of ultrasonography in the diagnosis of postsurgical recurrence of Crohn's disease. *Am J Gastroenterol* 1998; 93: 1117-21.
17. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. *Gut*. 2006; 55: 47-53.
18. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

- Gastroenterology. 2004; 127: 730-40.
19. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. *J Clin Gastroenterol* 1997; 25: 330-3.
  20. Armenti VT, Moritz MJ, Cardonick EH, Davison JM. Immunosuppression in pregnancy: choices for infant and maternal health. *Drugs* 2002; 62: 2361-75.
  21. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Hecker WP, Lavelanet A, McGroarty CH, Coscia LA. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. *Clin. Transpl.* 2004; 103-14.
  22. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. *Aliment Pharmacol Ther.* 2003 15; 17: 1451-7.
  23. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. *Hepatology*. 1999; 46: 1724-9.
  24. Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, Connors AF Jr, Cominelli F. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? *Clin Gastroenterol Hepatol* 2006; 4: 1135-42.
  25. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. *Inflamm Bowel Dis.* 2004; 10: 73-8.
  26. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double blind, placebo-controlled, crossover study. *Am J Gastroenterol*, 1992; 87: 432-7.
  27. Assche G van, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. *Gastroenterology*. 2003; 125: 1025-31.
  28. Assche G van, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology*. 2008; 134: 1861-8.
  29. Assche G van, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. *Am J Gastroenterol* 2003; 98: 332-9.
  30. Ausch C, Madoff RD, Gnant M, Rosen HR, Garcia-Aguilar J, Holbling N, Herbst F, Buxhofer V, Holzer B, Rothenberger DA, Schiessel R. Aetiology and surgical management of toxic megacolon. *Colorectal Dis.* 2006; 8: 195-201.
  31. Aveyard P, West R. Managing smoking cessation. *British Medical Journal*, 2007 7; 335 (7609): 37-41.
  32. Bach SP, Mortensen NJ. Revolution and evolution: 30 years of ileoanal pouch surgery. *Inflamm Bowel Dis.* 2006; 12: 131-45.
  33. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003; 348: 601-8.

34. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003; 348: 601-8.
35. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. *Gastroenterol* 1999; 116: 22-8.
36. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. *J.Clin.Gastroenterol* 1984; 6: 211-6.
37. Bais JM, Eskes M, Bonsel GJ. Determinanten van de hoge Nederlandse perinatale sterfte in Nederland in een volledig regional cohort. *Ned Tijdschr Geneesk.* 2004 Sep 18; 148 (38): 1873-8.
38. Baldassano R, Ferry G, Griffiths A, Mack D, Markowitz J, Winter H. Transition of the patiënt with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2002; 34: 245-8.
39. Ball EM. The nurse who is the patiënt: a personal perspective. *Gastroenterol Nurs.* 1997; 20: 129-35.
40. Bansal Gupta R, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. *Gastroenterol* 2007; 133: 1099-1105.
41. Barbosa DS, Cecchini R, Zebian M, et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. *Nutrition*, 2003; 19: 837-42.
42. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. *J Clin Gastroenterol* 2003; 36: 417-420.
43. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. *Gastroenterol* 1998; 115: 835-40.
44. Barot LR, Rombeau JL, Feurer ID, Mullen JL. Caloric requirements in patients with inflammatory bowel disease. *Ann Surg.* 1982; 195: 214-8.
45. Barot LR, Rombeau JL, Steinberg JJ, Crosby LO, Feurer ID, Mullen JL. Energy expenditure in patients with inflammatory bowel disease. *Arch Surg.* 1981; 116: 460-2.
46. Barreiro-de AM, Dominguez-Munoz JE, Nunez-Pardo de Vera MC, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. *Eur J Gastroenterol Hepatol* 2007; 19: 73-78.
47. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. *Aliment Pharmacol Ther* 2003; 18 (11-12): 1121-1127.
48. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. *Am J Gastroenterol* 2006; 101: 1048-56.

49. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. *Scan J Gastroenterol* 2001; 36: 71-6.
50. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. *Aliment.Pharmacol.Ther.* 2003, 17[9], 1145-51.
51. Beluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *New Engl J Medicine*, 1996; 334: 1557-60.
52. Bemelman WA, Slors JF, Dunker MS, et al. Laparoscopic-assisted vs. open ileocolic resection for Crohn's disease. A comparative study. *Surg Endosc* 2000; 14: 721-725.
53. Benoist S, Panis Y, Beaufour A, et al. Laparoscopic ileocecal resection in Crohn's disease: a case-matched comparison with open resection. *Surg Endosc* 2003; 17: 814-8.
54. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. *Annual Review Pharmacol Toxicol* 1996; 36: 597-613.
55. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. *Am J Surg* 2002, 184: 45-51.
56. Bergh FA van den, Kolkman JJ, Russel MG, Vlaskamp RT, Vermes I. Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease. *Ned Tijdschr Geneesk.* 2003; 147: 2360-5.
57. Berndtsson I, Öresland T, Hultén L. Sexuality in patients with ulcerative colitis before and after restorative proctocolectomy: a prospective study. *Scand J Gastroenterol* 2004; 39: 374-9.
58. Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. *Dis Colon Rectum* 2001; 44: 647-54; discussion 654.
59. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. *Thrombosis and Haemostasis* 2001; 85: 430-434.
60. Bernstein CN, Blanchard JF, Kliewer A, Wajda A. Cancer risk in patients with inflammatory bowel disease. *Cancer* 2001; 91: 854-62.
61. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med* 2000; 133: 795-9.
62. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. *Am J Gastroenterol* 2001; 96: 1116-22.
63. Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. *Inflamm Bowel Dis.* 2002; 8: 365-61.
64. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. *Gastroenterol* 2003; 124: 795-841.
65. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. *Aliment Pharmacol Ther* 1996; 10: 777-86.
66. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis. *Lancet* 1994; 343: 71-4.

67. Bernstein CN, Walker JR, Graff LA. On studying the connection between stress and IBD. *Am J Gastroenterol* 2006; 101: 782-5.
68. Bernstein CN. Cancer surveillance in inflammatory bowel disease. *Curr Gastroenterol Rep* 1999; 496-504.
69. Bernstein CN. Ulcerative colitis with low-grade dysplasia. *Gastroenterol* 2004; 127: 950-6.
70. Berstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. *Gastroenterol* 1980; 79: 357-65.
71. Best WR, Beckett JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterol* 1976; 70: 439-4.
72. Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner PB Jr. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. *Gastroenterology*. 1988; 94: 1075-9.
73. Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. *Gastroenterology*. 1990; 99: 113-8.
74. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. *Br J Ophthalmol* 2007; 91: 319-324.
75. Bievre MA de, Vrij AA, Schoon EJ, et al. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. *Inflamm Bowel Dis* 2007; 13: 753-758.
76. Binder HJ. Probiotic therapy with E.coli for ulcerative colitis: take the good with the bad. *Gastroenterol* 2000; 118: 630-5.
77. Birchard, K. R, Brown, M. A, Hyslop, W. B, Firat, Z, and Semelka, R. C. MRI of acute abdominal and pelvic pain in pregnant patients. *AJR Am.J.Roentgenol*. 2005; 184: 452-8.
78. Bjarnason I, Helgason KO, Geirsson AJ, et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. *Gastroenterol* 2003; 125: 1598-1605.
79. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997; 40: 228-233.
80. Björnsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. *Scand J Gastroenterol* 2004; 10: 961-8.
81. Bjoro K, Brandsaeter B, Foss A, Schrupf E. Liver transplantation in primary sclerosing cholangitis. *Semin Liver Dis* 2006; 26: 69-79.
82. Bleijenberg G, Bazelmans E, Prins J. Chronisch vermoeidheidssyndroom. Houten / Diegem: Bohn Stafleu Van Loghum, 2001.
83. Block G, Schraut W. The operative treatment of Crohn's enteritis complicated by ileosigmoid fistula. *Ann Surg* 1982; 196: 356-60.
84. Bodegraven AA van, Boer RO, Lourens J, Tuynman HA, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. *Aliment Pharmacol Ther*. 1996; 10: 327-32.
85. Bodegraven AA van, Linskens RK, van Haelst IM, Sindram JW, Tuynman HA. Addition of low-dose oral ciclosporine in severe ulcerative colitis--pharmacokinetics and clinical outcome report of twelve cases. *J Clin Gastroenterol* 1998; 27: 72-3.

86. Bodegraven AA van, Pena AS. Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease. *Curr Treat Options Gastroenterol* 2003; 6: 201-12.
87. Bodegraven AA van, Poen AC, Bakker EN. Tacrolimus suppositories in therapyrefractory ulcerative proctitis. *Gastroenterol* 2005; 128: A588.
88. Bodegraven AA van, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. *Dis Colon Rectum*. 2002; 45: 39-45; discussion 45-6.
89. Bodegraven AA van. Haemostasis in inflammatory bowel diseases: clinical relevance. *Scand J Gastroenterol Suppl* 2003; (239): 51-62.
90. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. *Scand J Gastroenterol* 2004; 39: 454-8.
91. Boer NK de, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Makelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD-patients. *World J Gastroenterol* 2005; 11: 5540-4.
92. Boer NK de, Elburg RM van, Wilhelm AJ, Remmink AJ, Van Vugt JM, Mulder CJ, Bodegraven AA van. 6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. *Scand.J Gastroenterol* 2005; 40: 1374-7.
93. Boer NK de, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkuhn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ; Dutch 6-TG working group. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. *Digestion*. 2006; 73: 25-31.
94. Boer NK de, Wong DR, Jharap B, de Graaf P, Hooymans PM, Mulder CJ, Rijmen F, Engels LG, van Bodegraven AA. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. *Am J Gastroenterol*. 2007; 102: 2747-53.
95. Boonen A, Dagnelie PC, Felius A, Hesselink MA, Muris JW, Stockbrugger RW, Russel MG. The Impact of inflammatory Bowel Disease on Labor Force Participation: Results of a Population Sampled Case-Control Study. *Inflammat Bowel Dis* 2002; 8: 382-9.
96. Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease. *Cochrane Database Syst Rev*. 2000; 2: CD000299.
97. Borgaonkar MR, Townson G, Donnelly M, Irvine EJ. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. *Inflammat Bowel Dis* 2002; 8: 264-9.
98. Borgiani P, Perricone C, Ciccacci C, Romano S, Elli G, Biancone L, Petruzzello C, Pallone F. Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population. *Gastroenterol* 2007; 133: 1049-51.
99. Borley NR, Mortensen NJ, Chaudry MA, Mohammed S, Warren BF, George BD, Clark T, Jewell DP, Kettlewell MG. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. *Dis Colon Rectum*. 2002; 45: 377-83.

100. Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. *Br J Surg.* 1997 ; 84: 1493-502.
101. Bosch van den BF, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. *Arthritis Rheum* 2002; 46: 755-65.
102. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Lancet.* 1996; 347: 215-9.
103. Brandt LJ, Berstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. *Gastroenterol* 1982; 83: 383-7.
104. Branski, D, Kerem, E, Gross-Kieselstein, E, Hurvitz, H, Litt, R, and Abrahamov, A. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. *J Pediatr.GastroenterolNutr.* 1986; 5: 316-7.
105. Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. *Ann Rheum Dis* 2004; 63: 1046-55.
106. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum* 2005; 52: 2447-51.
107. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002; 359 (9313): 1187-93.
108. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. *Eur J Gastroenterol Hepatol* 1996; 8: 225-8.
109. Brignola C, De Simone G, Belloli C, et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. *Aliment Pharmacol Ther.* 1994; 8: 465-8.
110. Broe P, Cameron J. Surgical management of ileosigmoid fistulas in Crohn's disease. *Am J Surg* 1982; 143: 611-3.
111. Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy. *Int J Colorectal Dis* 2001; 16: 81-7.
112. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. *Gut* 2006; 55: 505-9.
113. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzén H, Wallerstedt S, Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut.* 1996; 38: 610-5.
114. Buchanan G, Halligan S, Williams, et al. Effect of MRI on clinical outcome of recurrent fistula-in-ano. *Lancet* 2002; 360: 1661-2.
115. Buchanan GN, Bartram CI, Williams AB, Halligan S, Cohen CR. Value of hydrogen peroxide enhancement of three-dimensional endoanal ultrasound in fistula-in-ano. *Dis Colon Rectum* 2005; 48: 141-7.

116. Buchanan GN, Halligan S, Bartram CI, et al. Clinical Examination, Endosonography, and MR Imaging in Preoperative Assessment of Fistula in Ano: Comparison with Outcome-based Reference Standard. *Radiology* 2004; 233: 674-681.
117. Buchman AL, et al. Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. *Am J Gastroenterol* 2004; 99: 2171-7.
118. Buckley LM, Hillner BE. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. *J Reumatol* 2003; 30: 132-8.
119. Büning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Bühner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Büttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. *Aliment Pharmacol Ther* 2007; 26: 1025-33.
120. Burakoff R. Indeterminate colitis: clinical spectrum of disease. *J Clin Gastroenterol* 2004; 38 (5 suppl): 41-3.
121. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? *Clin Gastroenterol Hepatol* 2006; 4: 614-20.
122. Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? *Am J Gastroenterol* 2004; 99: 889-93.
123. Burnell D, Mayberry J, Calcraft BJ, Morris JS, Rhodes J. Male fertility in Crohn's disease. *Postgrad Med J* 1986; 62: 269-72.
124. Busato F, Alric L, Kamar N, Reynaud D, Bossavy JP, Duffaut M. Takayasu's arteritis and ulcerative colitis [3]. *Revue de Medecine Interne* 2000; 21: 907-909.
125. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci* 1989; 34: 1841-54.
126. Callahan MA, Christos PJ, Gold HT, Mushlin AI, Daly JM. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. *Ann Surg.* 2003; 238: 629-36; discussion 636-9.
127. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. *Gastroenterol* 1997; 113: 1465-73 [PMID: 9352848].
128. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. *Eur J Gastroenterol Hepatol* 2005; 17: 79-84.
129. Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. *Aliment Pharmacol Ther.* 2003; 17: 1471-80.
130. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. *Gut* 1997; 41: 209-14.
131. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? *Gastroenterol* 1999; 116: 1246-9.



132. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. *Aliment Pharmacol Ther* 2007; 25: 861-70.
133. Caprilli R, Angelucci E, Cocco A, et al. Appropriateness of immunosuppressive drugs in inflammatory bowel disease assessed by RAND method: Italian Group for IBD position statement *Dig Liver Dis* 2005; 37: 407-417.
134. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E et al, for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease : special situations. *Gut* 2006; 55 Suppl 1: i36-i58.
135. Capristo E, Addolorato G, Mingrone G, Greco AV, Gasbarrini G. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. *Am J Gastroenterol* 1998; 93: 2411-9.
136. Card T, West J, Hubbard R, Logan RFA. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: A population based cohort study. *Gut* 2004; 53: 251-255.
137. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. *J Nutr.* 2002; 132: 3146-50.
138. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. *Aliment Pharmacol Ther.* 2001; 15: 1989-99.
139. Carter FM, McLeod RS, Cohen Z. Subtotal colectomy for ulcerative colitis: complications related to the rectal remnant. *Dis Colon Rectum.* 1991 ; 34: 1005-9.
140. Casati J, Toner BB, De-Rooy EC, Drossman DA, Maunder RG. Concerns of patients with inflammatory bowel disease: A review of emerging themes. *Digestive Diseases and Sciences* 2000; 45: 26-31.
141. Castiglione, F, Pignata, S, Morace, F, Sarubbi, A, Baratta, M. A, D'Agostino, L, D'Arienzo, A, and Mazzacca, G. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. *Ital J Gastroenterol* 1996; 28: 199-204.
142. Castillo E, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. *Gastroenterol* 2003: 999.
143. Castillo E, Thomassie LM, Whitlow CB, Margolin DA, Malcolm J, Beck DE. Continent ileostomy: current experience. *Dis Colon Rectum.* 2005; 48: 1263-8.
144. Caudarella R, Rizzoli E, Pironi L, et al. Renal stone formation in patients with inflammatory bowel disease. *Scanning Microsc* 1993; 7: 371-379.
145. Cazzato IA, Cammarota G, Nista EC, Cesaro P, Sparano L, Bonomo V, Gasbarrini GB, Gasbarrini A. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. *Dig Liver Dis* 2007; 39: 483-7.
146. Challis S, Surgenor S. Helping patients with Crohn's disease to stop smoking. *Prof Nurse* 2004; 19: 386-9.
147. Champetier S, Bataillard A, Lallemand Y, et al. Good clinical practice in the dietetic management of cancer patients. *Bull Cancer* 2000; 87: 917-26.
148. Chapman AE, Levitt MD, Hewett P, et al. Laparoscopic-assisted resection of colorectal malignancies: a systematic review. *Ann Surg* 2001; 234: 590-606.

149. Charnock D, Sheppard S, Needham G and Gann R. An instrument for judging the quality of written consumer health information on treatment choices. *J Epidemiol Community Health* 1999; 53:105-111.
150. Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. *J Gastroenterol Hepatol* 2007; 22: 268-74.
151. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev* 2006; : CD004524.
152. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. *Cochrane Database Syst Rev* 2005: CD004800.
153. Cherian S, Singh P. Is routine ileoscopy useful? An observational study of procedure times, diagnostic yield, and learning curve. *Am J Gastroenterol* 2004; 99: 2324-9.
154. Choen S, Tsunoda A, Nicholls RJ. Prospective randomized trial comparing anal function after hand sewn ileoanal anastomosis with mucosectomy versus stapled ileoanal anastomosis without mucosectomy in restorative proctocolectomy. *Br J Surg*. 1991; 78: 430-4.
155. Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. *Gastrointest Endosc* 2005 ; 61: 255-61.
156. Cima RR, Pemberton JH. Medical and Surgical Management of Chronic Ulcerative Colitis. *Arch Surg*. 2005; 140: 300-10.
157. Cittadini G, Giasotto V, Garlaschi G, De Cicco E, Gallo A, Cittadini G. transabdominal ultrasonography of the small bowel after oral administration of a non-absorbable anechoic solution: comparison with barium enteroclysis. *Clin Radiol* 2001; 56: 225-30.
158. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. *Gut* 1993; 34: 1543-6.
159. Cochat, P, Decramer, S, Robert-Gnansia, E, Dubourg, L, and Audra, P. Renal outcome of children exposed to ciclosporine in utero. *Transplant.Proc.* 2004; 36: 208S-210S.
160. Cohen RD, Brodsky AL, Hanauer SB A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous ciclosporine. *Inflamm Bowel Dis*. 1999; 5: 1-10.
161. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. *Am J Gastroenterol* 2000; 95: 1263-76.
162. Collins CE, Cahill MR, Rampton DS. Clubbing in Crohn's disease. *BMJ* 1993; 307 (6902): 508.
163. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. *Gastroenterol* 2000; 118: 1025-30.
164. Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn's disease of the ileoanal pouch with infliximab. *Am J Gastroenterol* 2003; 98: 2239-44.

165. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007; 132: 52-65. Epub 2006 29.
166. Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. *Drug Saf* 1999; 21: 311-23.
167. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. *Gastroenterol* 1994; 107: 934-44.
168. Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW, Paraskevas P, Clark SK, Tekkis PP. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. *Dis Colon Rectum* 2007; 50: 1128-1138.
169. Cornish, J, Tan, E, Teare, J, Teoh, T. G, Rai, R, Clark, S. K, and Tekkis, P. P. A metaanalysis on the influence of inflammatory bowel disease on pregnancy. *Gut* 2007; 56: 830-7.
170. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. *Gut* 2001; 48: 186-90.
171. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. *Gastroenterology*. 1996; 110: 424-31.
172. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. *Gut* 1999; 45 : 165-6.
173. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. *Aliment Pharmacol Ther* 1999; 13: 1403-11.
174. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. *Best Pract Res Clin Gastroenterol* 2004; 18: 481–96.
175. Costamagna G, et al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. *Gastroenterol* 2002; 123: 999-1005.
176. Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. *Gastroenterol* 2000; 119: 597 [PMID: 10960274].
177. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. *Gastroenterol* 1994; 106: 643-8.
178. Coulam, C. B, Moyer, T. P, Jiang, N. S, and Zincke, H. Breast-feeding after renal transplantation. *Transplant.Proc.* 1982; 14: 605-9.
179. Coull DB, Lee FD, Henderson AP, Anderson JH, McKee RF, Finlay IG. Risk of dysplasia in the columnar cuff after stapled restorative proctocolectomy. *Br J Surg*. 2003; 90: 72-5.
180. Croog VJ, Ullman TA, Itzkowitz. Chemoprevention of colorectal cancer in ulcerative colitis. *Int J Colorectal Dis* 2003; 18: 392-400.
181. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. *Gut* 1996; 39: 401-6.

182. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. *World J Gastroenterol* 2004; 10: 1521-5.
183. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. *Semin Liver Dis* 2006; 26: 52-61.
184. Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. *Aliment Pharmacol Ther.* 2005; 21: 385-9.
185. Curtis JR, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. *Curr Osteoporos Rep* 2007; 5: 14-21.
186. CVZ. Diagnostisch Kompas [www.dk.cvz.nl](http://www.dk.cvz.nl) (geraadpleegd 16.9.2005).
187. Czeizel AE, Dudas, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N.Engl.J Med.* 1992; 327: 1832-5.
188. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. *Teratology* 1997; 56: 335-40.
189. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hooitegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 2008; 371: 660-7.
190. D'Haens G, Deventer S van, Van Hogezaand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. *Gastroenterol* 1999; 116: 1029-34.
191. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous ciclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. *Gastroenterology.* 2001; 120: 1323-9.
192. D'Haens G, MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. *Cochrane Database Syst Rev.* 2007 24: CD006097. Update of: *Cochrane Database Syst Rev.* 2006; 3: CD006097.
193. d'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, Bardazzi G, Milla M, Ferrero S, Biagini M, Quaranta S, Amorosi A. Combined therapy with 5aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. *Am J Gastroenterol* 1997; 92: 1143-7.
194. Danese S, Motte-Cd CL, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. *Am J Gastroenterol* 2004; 99: 938-945.
195. Danese S, Papa, A, Saibeni, S, Repici, A, Malesci, A, and Vecchi, M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. *Am.J Gastroenterol* 2007; 102: 174-186.
196. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. *World J Gastroenterol* 2005; 11 (46): 7227-36.
197. Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis. *Dig Liver Dis.* 2004; 36: 21-8.

198. D'Arienzo A, Manguso F, Castiglione GN, Vicinanza G, Scaglione G, Bennato R, Sanges M, Mazzacca G. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. *Ital J Gastroenterol Hepatol* 1998; 30: 254-7.
199. Daszak P, Purcell M, Lewin J, Dhillon AP, Pounder RE, Wakefield AJ. Detection and comparative analysis of persistent measles virus infection in Crohn's disease by immunogold electron microscopy. *J Clin Pathol* 1997; 50: 299-304.
200. Davies IH, Jenkins HR. Transition clinics for adolescents with chronic gastrointestinal disease in the UK and Ireland. *J Pediatr Gastroenterol Nutr.* 2003; 36: 505-6.
201. Deale A, Chalder T, Wessely SC, Keijsers GPJ, Hoogduin CAL. Protocolaire behandeling van patiënten met het chronisch vermoeidheidssyndroom: graduele activering en cognitieve therapie (156-191). Houten / Diegem: Bohn Stafleu Van Loghum, 2004.
202. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. *Aliment. Pharmacol. Ther.* 2003; 18: 1113-20.
203. Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G. Azathioprine treatment and male fertility in inflammatory bowel disease. *Gastroenterol* 2001; 121: 1048-53.
204. Delaney CP, Kiran RP, Senagore AJ, et al. Case-matched comparison of clinical and financial outcome after laparoscopic or open colorectal surgery. *Ann Surg* 2003; 238: 67-72.
205. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. *Ther Drug Monit* 2004; 26: 311-8.
206. De-Rooy EC, Toner BB, Maunder RG, Greenberg GR, Baron D, Steinhart AH, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. *Am J Gastroenterol* 2001; 96: 1816-21.
207. Désir B, Seidman EG. Transitioning the paediatric IBD-patient to adult care. *Best Pract Res Clin Gastroenterol* 2003; 17: 197-212.
208. Desjeux A, Barthet M, Barthellemy S, Dagorn JC, Hastier P, Heresbach D, Bernard JP, Grimaud JC. Serum measurements of pancreatitis associated protein in active Crohn's disease with ileal location. *Gastroenterol Clin Biol* 2002; 26: 23-8.
209. Deventer SJ van, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. *Aliment Pharmacol Ther* 2006; 23: 1415-25.
210. Di Leo V, D'Inca R, Barollo M, Tropea A, Fries W, Mazzon E, Irato P, Cecchetto A, Sturniolo GC. Effect of zinc supplementation on trace elements and intestinal metallothionein concentrations in experimental colitis in the rat. *Dig Liver Dis.* 2001; 33: 135-9.
211. Di Paolo MC, Paoluzi OA, Pica R, Iacopini F, Crispino P, Rivera M, Spera G, Paoluzi P. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. *Dig Liver Dis* 2001; 33: 563-9.

212. Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. *Nutrition*, 2000; 16: 87-90.
213. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. *Gastroenterology*, 1980; 79: 1199-204.
214. Dietrich CG, Lammert F. Beeinflusst Rauchen den Verlauf der Colitis ulcerosa? *Dtsch Med Wochenschr* 2002; 127: 2581-2.
215. Dietz DW, Laureti S, Strong SA, Hull TL, Church J, Remzi FH, Lavery IC, Fazio VW. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. *J Am Coll Surg*. 2001; 192: 330-7; discussion 337-8. *Dis Colon Rectum*. 2003; 46: 6-13.
216. D'Inca R, Sturniolo G, Cassaro M, di-Pace C, Longo G, Callegari I, Rugge M. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn's disease. *Dig Dis Sci* 1998; 43: 988-92.
217. Dornitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. *Am J Gastroenterol* 2002; 97: 641-8.
218. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. *Teratol* 1994; 49: 79-81.
219. Dor, R, Blanshard, C. Caution with the use of cyclosporin in pregnancy [letter]. *Gut* 2003; 52: 1070.
220. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der LS, Brandt J. Conventional treatments for ankylosing spondylitis. *Ann Rheum Dis* 2002; 61 Suppl 3: iii40-iii50.
221. Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI; Western Regional Research Alliance for Pediatric IBD. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. *Inflamm Bowel Dis* 2007; 13: 511-5.
222. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. *Gastroenterol* 2002; 122: 904-15.
223. Dudley-Brown S. Prevention of psychological distress in persons with inflammatory bowel disease. *Issues Ment Health Nurs*. 2002; 23: 403-22.
224. Duepre HJ, Senagore AJ, Delaney CP, et al. Advantages of laparoscopic resection for ileocecal Crohn's disease. *Dis Colon Rectum* 2002; 45: 605-610.
225. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barnada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*. 2006; 314: 1461-3.
226. Duijvendijk J van. Leven met Inflammatory Bowel Disease. De invloed van Colitis ulcerosa en de Ziekte van Crohn op het dagelijks functioneren en de kwaliteit van leven, Groningen, Wetenschapswinkel Geneeskunde en Volksgezondheid, 2004.
227. Duijvendijk J, Leven met IBD. Wetenschapswinkel. 2004 GV: 884.

228. Dunker MS, Bemelman WA, Slors JF, van Hogezaand RA, Ringers J, Gouma DJ. Laparoscopic-assisted vs open colectomy for severe acute colitis in patients with inflammatory bowel disease (IBD): a retrospective study in 42 patients. *Surg Endosc*. 2000; 14: 911-4.
229. Dunker MS, Stiggelbout AM, Hogezaand RA van, et al. Cosmesis and body image after laparoscopic-assisted and open ileocolic resection for Crohn's disease. *Surg Endosc* 1998; 12: 1334-40.
230. Dupuy A, Cosnes J, Revuz J, Delchier JC, Gendre JP, Cosnes A. Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. *Arch Dermatol* 1999; 135: 439-42.
231. Eaden JA, Abrams K, Ekbom A, Jackson A, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000; 14: 145-53.
232. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; 48 , 526-35.
233. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. *Gut* 2002; 51 (suppl): 10-2.
234. Eaden JA. Colorectal carcinoma and inflammatory bowel disease. *Aliment Pharmacol Ther* 2004: 24-30.
235. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous ciclosporine. *Am J Gastroenterol* 1998; 93: 442-8.
236. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. *Gastroenterol* 1999; 117: 1271-7.
237. Eijk I van der, Vlachonikolis IG, Munkholm P, et al. EC-IBD Study Group. The role of quality of care in health-related quality of life in patients with IBD. *Inflamm Bowel Dis*. 2004; 10: 392-8.
238. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. *Lancet* 1990; 336: 357-9.
239. El Maghraoui A, Dougados M, Freneaux E, Chaussade S, Amor B, Breban M. Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes in patients with spondylarthropathies and without clinical evidence of inflammatory bowel disease. *Reumatology* 1999; 38: 543-6.
240. Eliakim R, et al. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease. *Eur.J.GastroenterolHepatol* 2003; 15: 363-7.
241. Elloumi H, Ben Abdelaziz A, Derbel F, Jmaa A, Lassoued Y, Arfaoui D, Ben Ali A, Letaief R, Hamida RB, Ghannem H, Ajmi S. Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis. *Acta Gastroenterol Belg*. 2005; 68: 226-9.
242. Enck P, Schafer R. Psychosoziale Faktoren beim Crohn-eine Übersicht. (Psychosocial factors in Crohn's disease-an overview). *Z Gastroenterol* 1996; 34: 708-13.

243. Engel AF, Oomen JL, Knol DL, Cuesta MA. Operative mortality after colorectal resection in the Netherlands. *Br J Surg.* 2005; 92: 1526-32.
244. Engelsingjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. *Gastroenterol* 1999; 117: 1288-94.
245. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. *Scand J Gastroenterol* 2003; 38: 543-8.
246. Erichsen KR, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. *Scand J Gastroenterol* 2005; 40: 1058-65.
247. Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. *Lancet* 1999; 354 (9172): 43-4.
248. Esbjorner, E, Jarnerot, G, and Wranne, L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. *Acta Paediatr.Scand.* 1987; 76: 137-42.
249. Escher JC, Woude CJ van der. Transitie van de adolescent met een chronische inflammatoire darmziekte. *Tijdschr Kindergeneesk* 2005; 73: 36-41.
250. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. *Eur J Gastroenterol Hepatol* 2004; 16: 47-54.
251. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, Pepys MB. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. *Eur J Clin Invest* 1982; 12: 351-9.
252. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. *Am J Kidney Dis.* 1999; 33: 464-70.
253. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Populationbased study of risk of venous thromboembolism associated with various oral contraceptives. *Lancet.* 1997 11; 349 (9045): 83-8.
254. Farouk R, Dozois RR, Pemberton JH, Larson D. Incidence and subsequent impact of pelvic abscess after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Dis.Colon Rectum* 1998; 41: 1239-43.
255. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R. Natural history and prognostic variables in primary sclerosing cholangitis. *Gastroenterology.* 1991; 100: 1710-7.
256. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology.* 2003; 124: 917-24. Comment in: *Gastroenterol* 2003; 124: 1140-5. *Inflamm Bowel Dis* 2003; 9: 339-40.
257. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. *Am J Gastroenterol* 2000; 95: 3490-7.
258. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology.* 2001; 121: 255-60. Comment in: *Gastroenterol* 2002; 123: 393-5; author reply 395.



259. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. *Semin Liver Dis* 1991; 11: 31-39.
260. Fazio V. The dilemma of Crohn's disease: ileosigmoidal fistula complicating Crohn's disease. *Dis Colon Rectum* 1977; 20: 381-6.
261. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. *N Engl J Med*. 2000; 342: 1627-32.
262. Feagan BG, McDonald JW, Rochon J, et al. Low-dose ciclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. *N Engl J Med* 1994; 330: 1846-51.
263. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. A humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Aliment Pharmacol Ther*. 2006; 23: 617-28.
264. Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJ. Longterm follow-up of stricturoplasty for Crohn's disease. *Br J Surg* 2006; 93: 475-82.
265. Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. *Inflamm Bowel Dis* 2004; 10: 346-51.
266. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. *American Journal of Gastroenterol* 2000; 95: 1949-54.
267. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). *Am J Gastroenterol* 1998; 93: 1860-6.
268. Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, Loeschke K, Stange EF. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. *Aliment Pharmacol Ther*. 2000; 14: 171-6.
269. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). *Inflamm Bowel Dis*. 2002; 8: 317-24.
270. Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's disease. *Digestion*. 2005; 71: 26-8.
271. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. *Aliment Pharmacol Ther* 1998; 12: 175-83.
272. Ferlitsch A, Reinisch W, Püspök A, Dejaco C, Schillinger M, Schöfl R, Pötzi R, Gangl A, Vogelsang H. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. *Endoscopy*. 2006; 38: 483-7.
273. Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, Esteve M, Gonzalez-Huix F, Gassull MA. Vitamin status in patients with inflammatory bowel disease. *Am J Gastroenterol* 1989; 84: 744-8.

274. Fernandez-Banares F, Cabre E, Esteve-Coma M and Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A metaanalysis of the randomized clinical trials. *JPEN*, 1995; 19: 356-62.
275. Fidler HH, Avidan B, Lahav M, et al. Clinical and demographic characterization of Jewish Crohn's disease patients in Israel. *J Clin Gastroenterol* 2003; 36: 8-12.
276. Field EA, Allan RB. Review article: oral ulceration--aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. *Aliment Pharmacol Ther* 2003; 18: 949-62.
277. Fielding JF, Toye DK, Beton DC, Cooke WT. Crohn's disease of the stomach and duodenum. *Gut*. 1970; 11: 1001-6.
278. Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn's disease: a population study in central Israel. *Scand J Gastroenterol* 1989; 24: 346-50.
279. Fisher T. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. *N Engl J Med*. 1996 7; 334: 619-23.
280. Fix OK, Soto JA, Andrews CW, Farraye FA. Gastroduodenal Crohn's disease. *Gastrointest.Endosc.* 2004; 60: 985.
281. Folvik G, Bjerke-Larssen T, Ødegaard S, Hausken T, Gilja OH, Berstad A. Hydrosonography of the small intestine: comparison with radiologic barium study. *Scand J Gastroenterol* 1999; 12: 1247-52.
282. Folwaczny C. Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment? *Z Gastroenterol* 2000; 38: 547-50.
283. Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. *Am J Gastroenterol* 1998; 93: 2426-30.
284. Ford AC, Towler RJ, Moayyedi P, Chalmers DM, Axon AT. Mycophenolate mofetil in refractory inflammatory bowel disease. *Aliment Pharmacol Ther*. 2003; 17: 1365-9.
285. Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG. Musculoskeletal manifestations in inflammatory bowel disease. *Can J Gastroenterol* 2001; 15: 399-403.
286. Francella, A, Dyan, A, Bodian, C, Rubin, P, Chapman, M, and Present, D. H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. *Gastroenterol* 2003; 124: 9-17.
287. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: metaanalysis. *Radiology* 2005; 236: 95-101.
288. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. *Gut*. 2002; 50: 485-9.
289. Friedman S, Odze D, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. *Inflammatory Bowel Disease* 2003; 9: 260-6.
290. Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. *Gut* 2000; 47: 410-4.
291. Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC, Caprilli R. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. Oral plus topical treatment. *Aliment Pharmacol Ther*. 1999: 1413-7.

292. Fries W, Giofre MR, Catanoso M, Lo-Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. *Am J Gastroenterol* 2002; 97: 499500.
293. Froehlich F, Juillerat P, Mottet C, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P. Obstructive fibrostenotic Crohn's disease. *Digestion*. 2005; 71: 29-30.
294. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology*. 2007 Aug;133(2):412-22.
295. Fukushima T, Sugita A, Koganei K, Shinozaki M. The incidence and outcome of pelvic sepsis following handsewn and stapled ileal pouch anal anastomoses. *Surg Today*. 2000; 30: 223-7.
296. Gaetke LM, Stuart MA, Truszczynska H. A single nutrition counseling session with a registered dietitian improves short-term clinical outcomes for rural Kentucky patients with chronic diseases. *J Am Diet Assoc* 2006; 106: 109-12.
297. Ganguli SC, Cawdron R, Irvine EJ. Alternative medicine use by Canadian ambulatory gastroenterology patients: secular trend or epidemic? *Am J Gastroenterol* 2004; 99: 319-26.
298. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. *J Clin Gastroenterol* 2001; 32: 409-12.
299. García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. *Aliment Pharmacol Ther* 2005, 22, 309-15.
300. Garcia-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. *Behav Res Ther* 2004; 42: 367-83.
301. Gardiner SJ, Geary RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. *Br J Clin Pharmacol* 2006; 62: 453-6.
302. Gasche C, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis*. 2000; 6: 8-15.
303. Gasche C, Dejaco C, Reinisch W, Tillinger W, Waldhoer T, Fueger GF, Lochs H, Gangl A. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. *Digestion*. 1999; 60: 262-7.
304. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, Gangl A, Lochs H. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. *Ann Intern Med*. 1997; 126: 782-7.
305. Gasche C, Moser G, Tirtschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. *Gut* 1999; 44: 112-7.
306. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis*. 2000; 6: 8-15.
307. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, Petritsch W; Austrian Inflammatory Bowel Diseases Study Group. Prediction of response to iron

- sucrose in inflammatory bowel disease-associated anemia. *Am J Gastroenterol* 2001; 96: 2382-7.
308. Gassull MA, Fernandez-Banares F, Cabre E, Papo M, Gaffer MH, Sanchez-Lombrana JL, Richart C, Malchow H, Gonzalez-Huix F, Esteve M; European Group on Enteral Nutrition in Crohn's Disease. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. *Gut*. 2002; 51: 164-8.
  309. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? *Lancet* 2006 ; 367: 1271-84.
  310. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. *Am J Clin Nutr*. 1998; 67: 919-26.
  311. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. *Eur J Clin Nutr*. 2000; 54: 514-21.
  312. Geerling BJ, Lichtenbelt WD, Stockbrugger RW, Brummer RJ. Gender specific alterations of body composition in patients with inflammatory bowel disease compared with controls. *Eur J Clin Nutr*. 1999; 53: 479-85.
  313. Generini S, Fiori G, Matucci-Cerinic M. Therapy of spondylarthropathy in inflammatory bowel disease. *Clin Exp Rheumatol* 2002; 20 (6 Suppl 28): S88-S94.
  314. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. *Ann Rheum Dis* 2004; 63: 1664-9.
  315. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. *Radiology* 2002; 222: 645-51.
  316. Ghislain PD, De D, I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. *Br J Dermatol* 2004; 150: 1052-3.
  317. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterol* 1994; 107: 1031-9.
  318. Gaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn's disease. *Aliment Pharmacol Ther*. 1991; 5: 115-25.
  319. Giannadaki E, Potamianos S, Roussomoustakaki M, Kyriakou D, Fragkiadakis N, Mahousos ON. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. *American Journal of Gastroenterol* 1997; 92: 1872-4.
  320. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology*. 2003; 124: 1202-9.
  321. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzi D, Bazzocchi G, Poggioli G, Miglioli M and Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double blind, placebo-controlled trial. *Gastroenterology*, 2000; 119: 305-9.
  322. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. *J Gastroenterol Hepatol* 2000; 15: 489-93.

323. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. *Eur Rev Med Pharmacol Sci.* 1999; 3: 27-30.
324. Giudice PL, Dubourg L, Hadj-Aissa A, Said MH, Claris O, Audra P, Martin X, Cochat P. Renal function of children exposed to cyclosporin in utero. *Nephrol.Dial.Transplant.* 2000; 15: 1575-9.
325. Giwercman A, Skakkebaek NE. The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review. *Int J Androl* 1986; 9: 38-52.
326. Godet PG, Cowie R, Woodman RC, Sutherland LR. Pulmonary function abnormalities in patients with ulcerative colitis. *Am J Gastroenterol* 1997; 92: 1154-6.
327. Goischke HK. Thematisierung des Nikotinabusus durch den Gastroenterologen –welcher Benefit ist von einer engagierten Raucherentwönung zu erwarten – insbesondere bei Crohn? *Prävention und Rehabilitation* 2003; 16: 164-74.
328. Gonzales-Huix F, Fernandez-Banares F, Esteve-Comas M, Abad-Lacruz A, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. *Am J Gastroenterol*, 1993; 88: 227-32.
329. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. *Dig Dis Sci.* 2006; 51: 1833-40.
330. Gordon F. Recurrent primary sclerosing cholangitis: Clinical diagnosis and long-term management issues. *Liver Transpl* 2006; 12 (11 Suppl 2): S73-S75.
331. Gorgun E, Remzi FH, Goldberg JM, Thornton J, Bast J, Hull TI, Loparo B, Fazio VW. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. *Surgery* 2004; 136: 795-803.
332. Gozzetti G, Poggioli G, Marchetti F, Laureti S, Grazi GL, Mastroilli M, Selleri S, Stocchi L, Di Simone M. Functional outcome in handsewn versus stapled ileal pouch-anal anastomosis. *Am J Surg.* 1994; 168: 325-9.
333. Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. *Clin Gastroenterol Hepatol* 2006; 4: 1491-1501.
334. Green CJ. Existence, causes and consequences of disease related malnutrition in the hospital and the community, and clinical and financial benefits of nutritional intervention. *Clinical Nutrition* 1999; 18 (suppl 2): 3-28.
335. Green JR, Lobo AJ, Giaffer M, Travis SPL, Watkins HC. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. *Aliment Pharmacol Ther* 2001; 15: 1331-41.
336. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. *N Engl J Med* 1994; 331: 836-41.
337. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. *Gastroenterol* 1996; 110: 45-51.
338. Greenstein AJ, Horowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)* 1976; 55: 401-12.

339. Greenstein AJ, Present D, Sachar D, et al. Gastric fistulas in Crohn's disease. Report of cases. *Dis Colon Rectum* 1989; 32: 888–9218.
340. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. *Medicine (Baltimore)* 1992; 71: 261270.
341. Grekas, D. M, Vasiliou, S. S, and Lazarides, A. N. Immunosuppressive therapy and breast-feeding after renal transplantation [letter]. *Nephron* 1984; 37: 68.
342. Griffiths AM, Alemayehu E, Sherman P. Clinical features of gastroduodenal Crohn's disease in adolescents. *J Pediatr Gastroenterol Nutr* 1989; 8: 166-71.
343. Griffiths AM, Ohlsson A, Sherman PM and Sutherland L. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. *Gastroenterol* 1995; 108: 1056-67.
344. Grobler SP, Hosie KB, Keighley MR. Randomized trial of loop ileostomy in restorative proctocolectomy. *Br J Surg.* 1992 Sep; 79: 903-6.
345. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. *Eur J Gastroenterol Hepatol* 1996; 8: 905-9.
346. Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. *Gut* 1998; 42: 493-6.
347. Gumaste V, Greenstein AJ, Meyers R, Sachar DB. Coombs-positive autoimmune hemolytic anemia in ulcerative colitis. *Dig Dis Sci* 1989; 34: 1457-61.
348. Gupta I, Parihar A, Malhotra P, et al. Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *Eur J Med Res* 1997; 2: 37-43.
349. Guslandi M, Giollo P and Testoni PA. A pilot trial of *saccharomyces boulardii* in ulcerative colitis. *Eur J of Gastroenterol and Hepatol*, 2003; 15: 697-8.
350. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. *Gastroenterol* 2000; 119: 639-46.
351. Haggett PJ, Moore NR, Shearman JD, Travis SPL, Jewell DP, Mortensen NJ. Pelvic and perineal complications of Crohn's disease: Assessment using magnetic resonance imaging. *Gut* 1995; 36: 407-10.
352. Hahnloser, D, Pemberton, J. H, Wolff, B. G, Larson, D, Harrington, J, Farouk, R, and Dozois, R.R. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. *Dis.Colon Rectum* 2004; 47: 1127-35.
353. Hait E, Arnold JH, Fishman LN. Educate, communicate, anticipate-practical recommendations for transitioning adolescents with IBD to adult health care. *Inflamm Bowel Dis.* 2006; 12: 70-3.
354. Halfvarson, J, Bodin, L, Tysk, C, Lindberg, E, and Järnerot, G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. *Gastroenterol* 2003; 124: 1767-73.
355. Hallert C, Björck I, Nyman M, Ousette A, Grännö C and Svensson H. Increasing fecal butyrate in Ulcerative colitis patients by diet: controlled pilot study. *Inflammatory bowel disease*, 2003; 9: 116-21.

356. Hallgren TA, Fasth SB, Oresland TO, Hulten LA. Ileal pouch anal function after endoanal mucosectomy and handsewn ileoanal anastomosis compared with stapled anastomosis without mucosectomy. *Eur J Surg*. 1995; 161: 915-21.
357. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. *Lancet*. 2001; 357: 1925-8.
358. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, Mirza MM, Foelsch UR, Vatn M, Schreiber S. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. *Lancet* 2002; 359: 1661-5.
359. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and inflammatory bowel disease. *Gastroenterol Clin North Am*. 1999; 28: 423-43.
360. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet*. 2002; 359: 1541-9.
361. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. *Gastroenterology*. 1998; 115: 525-32.
362. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. *Am J Gastroenterol* 2005; 100: 85.
363. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. *Gastroenterology*. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. 2006; 130: 323-33; quiz 591. Comment in: *Gastroenterology*. 2006; 130: 1929-30.
364. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. *Clin Gastroenterol Hepatol* 2004; 2: 379-88.
365. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin Gastroenterol Hepatol* 2004; 2: 542-53.
366. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. *Inflamm Bowel Dis*. 1998; 4: 79-83.
367. Handelsman JC, Gottlieb LM, Hamilton SR. Crohn's disease as a contraindication to Kock pouch (continent ileostomy). *Dis Colon Rectum* 1993; 36: 840-3.
368. Hansmann HJ, Kosa R, Dux M, et al. Hydro-MRI of chronic inflammatory bowel disease. *Fortschr Röntgenstr* 1997; 167: 132-8.

369. Hara AK, Leighton JA, Sharma VK, Heigh RI, Fleischer DE. Imaging of small bowel disease: comparison of capsule endoscopy, standard endoscopy, barium examination, and CT. *Radiographics* 2005; 25: 697-711.
370. Harms PW, Kardam SH, Elema J, Van-Voorst-Vader PC. Cheilitis granulomatosa: syndroom van Melkersson-Rosenthal versus ziekte van Crohn. [Cheilitis granulomatosa: syndrome of Melkersson-Rosenthal vs. Crohn's disease]. *Ned Tijdschr Geneesk* 2000; 144 (32): 1562-1563.
371. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. *Br Med J (Clin Res Ed)* 1982; 284: 706.
372. Hart W. (The new CBO-guideline 'Osteoporosis' is a broadly supported standard for clinical practice). *Ned Tijdschr Geneesk* 2002; 146 (29): 1352-1354.
373. Hashemi M, Ell JR, Lewis AA. Side-to-side stapled anastomosis may delay recurrence in Crohn's disease. *Dis Colon Rectum* 1998; 41: 1293-6.
374. Hassan C, Cerro P, Zullo A, Spina C, Morini S. Computed tomography enteroclysis in comparison with ileoscopy in patients with Crohn's disease. *Int J Colorectal Dis* 2003; 18: 121-5.
375. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomized controlled trial. *Gut*, 1992; 33: 922-8.
376. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. *BMJ*. 1992; 305: 20-2.
377. Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: Reproduction in the patient with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2007 15; 26: 513-33.
378. Heijde HD van der, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005; 52: 582-591.
379. Heijde HD van der, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006; 54: 2136-2146.
380. Heinmann T. Surgical management of ileosigmoid fistulas in Crohn's disease. *Am J Gastroenterol* 1979; 72: 21-4.
381. Heit JA, Melton LJ, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. *Mayo Clin Proc* 2001; 76: 1102-10.
382. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med* 2002; 162: 1245-8.
383. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. *Gut* 1980; 21: 525-7.
384. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. *Am J Gastroenterol* 2006; 101: 119-23.
385. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN Study). *Scand J Gastroenterol* 2006; 41:



1037-43.

386. Heresbach D, Bretagne JF, Raoul JL, et al. Indium scanning in assessment of acute Crohn's disease. *Dig Dis Sci* 1993; 38: 1601-7.
387. Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. *Am J Gastroenterol* 2002; 97: 377-381.
388. Heuman R, Boeryd B, Bolin T, Sjodahl R. The influence of disease at the margin of resection on the outcome of Crohn's disease. *Br J Surg* 1983; 70: 519-21.
389. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related complications in ulcerative colitis and familial adenomatous polyposis. *Ann Surg* 2002; 235: 207-16.
390. Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. One- or twostage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. *Ann Surg*. 2001; 234: 788-94.
391. Hill, J, Clark, A, and Scott, N. A. Surgical treatment of acute manifestations of Crohn's disease during pregnancy. *J.R.Soc.Med.* 1997; 90: 64-6.
392. Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR. Helping patients with Crohn's disease quit smoking. *Am J Gastroenterol* 2000; 95: 352-8.
393. Hirano K, Kawabe T, Yamamoto N, et al. Serum IgG4 concentrations in pancreatic and biliary diseases. *Clin Chim Acta* 2006; 367 (1-2): 181-4.
394. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. *Aliment Pharmacol Ther* 2006; 24: 319-30.
395. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. *N Engl J Med* 1969; 281: 397-402.
396. Holleland G, Schneede J, Ueland PM, Lund PK, Refsum H, Sandberg S. Cobalamin deficiency in general practice. Assessment of the diagnostic utility and cost-benefit analysis of methylmalonic acid determination in relation to current diagnostic strategies. *Clin Chem*. 1999; 45: 189-98.
397. Holmes AL, Sanderson B, Maisiak R, Brown A, Bittner V. Dietitian services are associated with improved patient outcomes and the MEDFICTS dietary assessment questionnaire is a suitable outcome measure in cardiac rehabilitation. *J Am Diet Assoc*. 2005; 105: 1533-40.
398. Hommes DW, Baert F, Van Assche G, et al. Management of recent onset Crohn's disease: A controlled, randomized trial comparing Step-up and Top-down therapy. *Gastroenterol* 2005; 129, 371.
399. Horst HE van der, Meijer JS, Muris JWM, Sprij B, Visser FMPB, Romeijnders ACM, et al. NHG-standaard. Prikkelbaredarmsyndroom. *Huisarts Wet* 2001; 44: 58-65.
400. Horst HE van der, Muris JWM, Pop P. Chronische buikpijn. *Huisarts Wet* 2003; 46: 627-32.
401. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. *Radiology* 2008;247:64-79
402. Hudson E, Dore C, Sowter C, Toovey S, Levi AJ. Sperm size in patients with inflammatory bowel disease on sulfasalazine therapy. *Fertil Steril* 1982; 38: 77-84.

403. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NAG, Fertility and pregnancy in inflammatory bowel disease. *Int J Gynecol Obstet* 1997; 58: 229-37.
404. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. *Dig Surg.* 2005; 22 (1-2): 69-79.
405. Hueting WE, Gooszen HG, Laarhoven CJHM van. Sexual function and continence after ileo pouch anal anastomosis: a comparison between a meta-analysis and a questionnaire survey. *Int J Colorectal Dis* 2004; 19: 215-8.
406. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001; 411: 599-603.
407. Hulten L, Kewenter J, Ahren C. Precancer and carcinoma in chronic ulcerative colitis. A histopathological and clinical investigation. *Scand J Gastroenterol* 1972; 7: 663-9.
408. Husain A, Triadafilopoulos G. Communicating with patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2004; 10: 444-50.
409. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. *Gastroenterology* 2007;133:1779-86.
410. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. *Dis Colon Rectum.* 2006; 49: 1837-41.
411. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. *Dis Colon Rectum.* 2005; 48: 70-3.
412. Hyman NH, Fazio VW, Tuckson WB, Lavery IC. Consequences of ileal pouch-anal anastomosis for Crohn's colitis. *Dis Colon Rectum* 1991; 34: 653-7.
413. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. *J Clin Gastroenterol* 2000; 30: 200-2.
414. Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. *Dig Surg* 2000; 17: 493-6.
415. Ilnyckji, A, Blanchard, J. F, Rawsthorne, P, and Bernstein, C. N. Perianal Crohn's disease and pregnancy: role of the mode of delivery. *Am J Gastroenterol* 1999; 94: 3274-8.
416. Imes S, Pinchbeck BR, Thomson AB. Diet counseling modifies nutrient intake of patients with Crohn's disease. *J Am Diet Assoc* 1987; 87: 457-62.
417. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J* 2000; 15: 373-81.
418. Ingram JR, Rhodes J, Evans BK, Newcombe RG, Thomas GA. Comparative study of enema retention and preference in ulcerative colitis. *Postgrad Med J.* 2005; 81: 594-8.
419. Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S. A randomized trial of nicotine enemas for active ulcerative colitis. *Clin Gastroenterol Hepatol* 2005; 3: 1107-14.
420. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease.

- Clin.GastroenterolHepatol 2005; 3: 617-628.
421. Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. *Br J Cancer* 2004; 91: 447-52.
  422. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J Am Coll Nutr.* 2003; 22: 56-63.
  423. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel disease. *Gastroenterol* 2004; 126: 1634-48.
  424. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997; 40: 313-9.
  425. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. *Scand J Gastroenterol* 2004; 39: 145-53.
  426. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. *Scand J Gastroenterol* 2002; 37: 192-9.
  427. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. *Am J Gastroenterol* 1984; 79: 533-40.
  428. Jantschek G, Zeitz M, Pritsch M, Wirsching M, Klor HU, Studt HH, et al. Effect of psychotherapy on the course of Crohn's disease. Results of the German Prospective Multicenter Psychotherapy Treatment Study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's disease. *Scand J Gastroenterol* 1998; 33: 1289-96.
  429. Jarnerot G, Hertvig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology.* 2005; 128: 1805-11.
  430. Jarnerot, G, Into-Malmberg, M. B, and Esbjorner, E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. *Scand.J.Gastroenterol* 1981; 16: 693-7.
  431. Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. *J. Clin. Gastroenterol* 2000; 30: 294-8.
  432. Jess T, Gomborg M, Munkholm P, et al. Overall and Cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. *Am J Gastroenterol* 2007; 102: 609-17.
  433. Jess T, Loftus EV, Harmsen WE, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. *Gut* 2006; 55: 1248-54.
  434. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease : a population-based study from Olmsted county, Minnesota. *Gastroenterol* 2006; 130: 1039-46.
  435. Jick H, Walker AM. Cigarette smoking and ulcerative colitis. *N Engl J Med* 1983; 308: 261-3.

436. Johnson P, Richard C, Ravid A, Spencer L, Pinto E, Hanna M, Cohen Z, McLeod R. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. *Dis Colon Rectum* 2004; 47: 1119-26.
437. Jones SC, Gallacher B, Lobo A.J., et al. A patiënt knowledge questionnaire in IBD. *J. Clin Gastroenterol* 1993 ; 17 (a) : 21-4.
438. Jong DJFH de. Corstens L, Mannaerts LG, Rossum van, Naber AH, Corticosteroidinduced osteoporosis: does it occur in patients with Crohn's disease? *Am J Gastroenterol* 2002; 97: 2011-5.
439. Joo JS, Weiss EG, Nogueras JJ, Wexner SD. Endorectal advancement flap in perianal Crohn's disease. *Am.Surg.* 1998, 64 (2), 147-50.
440. Joos S, Brinkhaus B, Maluche C, et al. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. *Digestion* 2004; 69: 131-9.
441. Joos S, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. *Scand J Gastroenterol* 2006; 41: 1056-63.
442. Juhasz ES, Fozard B, Dozois RR, Ilstrup DM, Nelson H. Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. *Dis Colon Rectum* 1995; 38: 159-65.
443. Juillerat P, Mottet C, Froehlich F, et al. Extraintestinal manifestations of Crohn's disease. *Digestion* 2005; 71: 31-36.
444. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut* 2007; 56: 1706-13.
445. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. *Am J Gastroenterol* 2001; 96: 2929-33.
446. Kane SV, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. *Am J Med* 2003; 114: 39-43.
447. Kane SV, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. *Am J Gastroenterol* 2004; 99: 1523-6.
448. Kane SV, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. *Am J Gastroenterol* 2005; 100: 102-5.
449. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. *Aliment Pharmacol Ther.* 2006; 23: 577-85.
450. Karsdorp NJGH, Korten J.-W. Handboek Arbeid en Belastbaarheid Bohn Stafleu Van Loghum 1999.
451. Kato K, Mizuno S, Umesaki Y, Ishi Y, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A and Arakawa Y. *Aliment pharmacol ther*, 2004; 20: 1133-41.
452. Katz, J. A, Antoni, C, Keenan, G. F, Smith, D. E, Jacobs, S. J, and Lichtenstein, G. R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and reumatoid arthritis. *Am J Gastroenterol* 2004; 99: 2385-92.
453. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001; 345 (15): 1098-1104.

454. Keller W, Pritsch M, Von Wittersheim J, Scheib P, Osborn W, Balck F, et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment Study on Crohn's disease. *J Psychosom Res.* 2004; 56: 687-96.
455. Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, et al. A randomised controlled trial to assess the impact of a package comprising a patient-oriented, evidence-based self-help guidebook and patient-centered consultations on disease management and satisfaction in inflammatory bowel disease. *Health Technol Assess* 2003; 7: 1-113.
456. Kennedy A, Robinson A, Hann M, Thompson D. A cluster-randomised controlled trial of a patient-centred guidebook for patients with ulcerative colitis: effect on knowledge, anxiety and quality of life. *Health Soc Care Community* 2003; 11: 64-72.
457. Kerry JE, Marshall C, Griffiths PA, James MW, Scott BB. Comparison between TcHMPAO labeled white cells and Tc Leukoscan in the investigation of inflammatory bowel disease. *Nucl Med Comm* 2005; 26: 245-51.
458. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. *Gut* 1984; 25: 52-6.
459. Khurram BM, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. *Colorectal Dis* 2004; 6: 250-253.
460. Kiesslich R, Fritsch J, Holtmann M, et al. Methlene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and coloncancer in ulcerative colitis. *Gastroenterol* 2003; 124: 880-8.
461. Kimber RD, Roberts-Thomson IC. Gastrointestinal: Crohn's disease of the oesophagus. *J.Gastroenterol Hepatol* 2000; 15: 959.
462. Kitayama T, Funayama Y, Fukushima K, Shibata C, Takahashi K, Ogawa H, Ueno T, Hashimoto A, Sasaki I. Anal function during pregnancy and postpartum after ileal pouch anal anastomosis for ulcerative colitis. *SurgToday* 2005; 35: 211-5.
463. Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B and folate. *Clin Chem.* 2000; 46: 1277-83.
464. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. *Am.J.Clin.Nutr.* 2004; 80: 1342-52.
465. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. *Lancet* 1993; 342: 618-9.
466. Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. *Am J Roentgenol* 1989; 152: 999-1003.
467. Koh DM, Miao Y, Chinn RJS, et al. MR imaging evaluation of the activity of Crohn's disease. *AJR* 2001; 177: 1325-32.
468. Kohn A, Cerro P, Milite G, De Angelis E, Prantera C. Prospective evaluation of transabdominal bowel sonography in the diagnosis of intestinal obstruction in Crohn's disease: comparison with plain abdominal film and small bowel enteroclysis. *Inflamm Bowel Dis* 1999; 5: 153-7.
469. Kolkman JJ, Falke THM, Roos JC, et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. *Dig Dis Sci* 1996; 41: 641-50.

470. Kolkman JJ, Mollmann HW, Mollmann AC, Pena AS, Greinwald R, Tauschel HD, Hochhaus G. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. *Drugs Today (Barc)*. 2004; 40: 589-601.
471. Kontos AP, Kerr HA, Fivenson DP, Remishofsky C, Jacobsen G. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. *Int J Dermatol* 2006; 45: 1383-5.
472. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6mercaptopurine in the treatment of Crohn's disease. *Am J Gastroenterol* 1993; 88: 1198-205.
473. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update). *Am J Gastroenterol* 2004; 99: 1371-85.
474. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2: 266-272.
475. Krause M. The transformation of social representations of chronic disease in a self-help group. *Journal Health Psychology* 2003; 8: 599-615.
476. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald, R. The optimal dose of 5aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. *Clin Gastroenterol Hepatol* 2003; 1: 36-43.
477. Kruis W, Frič P, Lukáš, Fixa B, Kaščák M, Kamm MA, Beglinger C, Stolte M, Wolff C and Schulze J. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004; 53: 1617-23.
478. Kruizenga HM, Seidell JC, De Vet HCW, Wierdsma NJ, Van Bokhorst - de van der Schueren MAE. Development and validation of a hospital screening tool: the Short Nutritional assessment Questionnaire (SNAQ) *Clinical Nutrition* 2005, 24: 75-82.
479. Kruizenga HM, Tulder MW van, Seidell JC, Thijs A, Ader HJ, Van Bokhorst - de van der Schueren MAE. Effectiveness and cost effectiveness of early screening and treatment of malnourished patients. *The American Journal of Clinical Nutrition* 2005; 82: 1082-9.
480. Kubba A, Guillebaud J. Combined oral contraceptives: acceptability and effective use. *British Medical Bulletin* 1993; 49: 140-57.
481. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease: *Aliment Pharmacol Ther* 2006; 24: 1507-23.
482. Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5aminosalicylic acid-based drugs: a case report and review of the literature. *Ann Allergy Asthma Immunol*. 2006 Sep;97(3):284-7.
483. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. *World J Gastroenterol* 2003; 9: 2300-7.
484. Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, Caramelli E, Fiorentino M, d'Errico A, Volk HD, Campieri M. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. *Inflamm Bowel Dis*. 2005; 11: 447-54.

485. Lange A, Haslbeck E, Andus T, Bregenzer N, Gross V, Scholmerich J, et al. Ambulante Schulung bei Patienten mit Crohn/Colitis ulcerosa. (Ambulatory education of patients with Crohn's disease/ulcerative colitis). *Z Gastroenterol* 1996; 34: 411-5.
486. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis. A study on the course and prognostic factors. *Scand J Gastroenterol* 1996; 31: 260-6.
487. Langhorst J, Eisenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices. *Am J Gastroenterol* 2008; 103: 162-9.
488. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebocontrolled trial of oral aloe vera gel for active ulcerative colitis. *Aliment Pharmacol Ther* 2004; 19: 739-47.
489. Larsson K, Sundberg-Hjelm M, Karlbom U, Nordin K, Anderberg UM, Loof L. A groupbased patient education programme for high-anxiety patients with Crohn's disease or ulcerative colitis. *Scand J Gastroenterol* 2003; 38: 763-9.
490. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. *Gastroenterol* 1997; 112: 29-32.
491. Lashner BA, Watson AJ. Colorectal cancer in ulcerative colitis: surveillance. In: McDonald JWD, Burroughs AK, Feagan BG, editors. *Evidence based gastroenterology and hepatology*. London: BMJ Books, 1999: 221-9.
492. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2006; 3: CD 005112.
493. Lecomte T, Contou JF, Beauverie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Predictive factors of response of perianal Crohn's disease to azathioprine or 6mercaptopurine. *Dis. Colon Rectum*. 2003 ; 46: 1469-75.
494. Lee BF, Chiu NT, Wu DC, et al. Use of 99mTc(V)DMSA scintigraphy in the detection and localization of intestinal inflammation: comparison of findings at colonoscopy and biopsy. *Radiology* 2001; 220: 381-5.
495. Leighton JA, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. *Gastrointestinal Endoscopy* 2006; 63: 558-65.
496. Leiper K, Woolner J, Mullan MC, Parker T, van der Vliet M, Fear S, Rhodes JM and Hunter JO. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. *Gut*, 2001; 49: 790-4.
497. Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y; Groupe D'Etude Therapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. *Gastroenterology*. 2005; 128: 1812-8.
498. Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF. Methotrexate in Crohn's disease: long-term efficacy and toxicity. *Am J Gastroenterol* 2000; 95: 1730-4.

499. Lemon CC, Lacey K, Lohse B, Hubacher DO, Klawitter B, Palta M. Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. *J Am Diet Assoc* 2004; 104: 1805-15.
500. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. *Gut* 2002; 51: 143-6.
501. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CW, Jones FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. *Gut* 1960; 1: 217-22.
502. Lepisto AH, Jarvinen HJ. Durability of Kock continent ileostomy. *Dis Colon Rectum*. 2003; 46: 925-8.
503. Lepisto AH, Jarvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. *Scand J Surg*. 2005; 94: 40-2. 62.
504. Pastore RL, Wolff BG, Hodge D. Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease. *Dis Colon Rectum*. 1997; 40: 1455-64.
505. Lertsithichai P, Rattanapichart P. Temporary ileostomy versus temporary colostomy: a meta-analysis of complications. *Asian J Surg*. 2004; 27: 202-10; discussion 211-2.
506. Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M,not AS, Thomas G, Hugot JP; EPWG-IBD Group; EPIMAD Group; GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. *Am J Hum Genet*. 2002; 70: 845-57.
507. Levi AJ, Fisher AM, Hughes L, Hendry WF. Male infertility due to sulphasalazine. *Lancet* 1979; 2: 276-8.
508. Levitsky J, Harrison JR, Cohen RD. Crohn's disease and Takayasu's arteritis. *J Clin Gastroenterol* 2002; 34: 454-456.
509. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol* 2006; 4: 621-30. Erratum in: *Clin Gastroenterol Hepatol* 2006; 4: 931.
510. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. *Gastroenterol* 2005; 128: 862-9.
511. Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. *Gut* 2003; 52: 1127-32.
512. Limberg B, Osswald B. Diagnosis and differential diagnosis of ulcerative colitis and Crohn's disease by hydrocolonic sonography. *Am J Gastroenterol* 1994; 89: 1051-7.
513. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. *Am J Gastroenterol* 2000; 95: 2831-7.
514. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. *Gut* 1992; 33: 779-82.
515. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *N Engl J Med* 1997; 336: 691-5.



516. Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. *Dig Dis Sci.* 2001; 46: 644-8.
517. Lloyd DA, Payton KB, Guenther L, Frydman W. Melkersson-Rosenthal syndrome and Crohn's disease: one disease or two? Report of a case and discussion of the literature. *J Clin Gastroenterol* 1994; 18: 213-7.
518. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. *QJM.* 1999; 92: 551-63.
519. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. *Gastroenterol* 2000; 118: 264-73. Erratum in: *Gastroenterol* 2000 ; 119: 280.
520. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 2004; 113: 1296-306.
521. Loeschke K, Ueberschaer B, Peitsch A, et al. N-3 fatty acids only delay early relapse of ulcerative colitis in remission. *Dig Dis Sci.* 1996; 41: 2087-94.
522. Lofberg R, Ostergaard Thomsen O, Langholz E, Schioler R, Danielsson A, Suhr O, Graffner H, Pahlman L, Matzen P, Moller-Petersen JF, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. *Aliment Pharmacol Ther.* 1994; 8: 623-9.
523. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. *Gut* 1996; 39: 82-6.
524. Loftus EV, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ, III. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. *Clin Gastroenterol Hepatol* 2003; 1: 465-473.
525. Loftus EV, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. *Hepatology* 1998; 27: 685-90.
526. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ, III. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. *Gastroenterol* 2002; 123: 468-75.
527. Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell JJ. Intake of dietary iron is low in patients with Crohn's disease: a case-control study. *Br J Nutr.* 2004; 91: 141-8.
528. Longo WE, Ballantyne GH, Cahow CE. Treatment of Crohn's colitis. Segmental or total colectomy? *Arch Surg* 1988; 123: 588-90.
529. Longobardi T, Jacobs P, Bernstein CN. Work Losses Related to Inflammatory Bowel Disease in the United States: Results From the National Health Interview Survey. *Amer J Gastroenterol* 2003; 98: 1064-72.
530. Lorenz Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multi center trial. Study group members. *Scand J Gastroenterol.* 1996; 31: 778-85.

531. Lorenz R, Weber PC, Szimnau P, et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease – a randomized, placebo-controlled, doubleblind cross-over trial. *J Inter Med Suppl*, 1989; 731: 225-32.
532. Low RN, Francis IR, Politoske D, Bennett Crohn's disease evaluation: comparison of contrast-enhanced MR imaging and single-phase helical CT scanning. *JMRI* 2000; 11: 127-35.
533. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatmentrefractory Crohn's disease perianal fistulae. *Inflamm Bowel Dis* 1999; 5: 239–45.
534. Luukkonen P, Jarvinen H. Stapled vs hand-sutured ileoanal anastomosis in restorative proctocolectomy. A prospective, randomized study. *Arch Surg*. 1993; 128: 437-40.
535. Lyon CC, Stapleton M, Smith AJ, Mendelsohn S, Beck MH, Griffiths CE. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. *J Dermatolog Treat* 2001; 12: 13-7.
536. Maartense S, Dunker MS, Slors JF, Cuesta MA, Gouma DJ, van Deventer SJ, van Bodegraven AA, Bemelman WA. Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. *Ann Surg* 2004; 240: 984-91; discussion 991-2.
537. Maartense S, Dunker MS, Slors JF, Cuesta MA, Pierik EGJM, Gouma DJ, Hommes DW, Sprangers MA, Bemelman WA. Laparoscopic versus open ileocolic resection for Crohn's disease. A randomized trial. *Ann Surg* 2006; 243: 143-9; discussion 150-3.
538. Macarthur C, Glazener C, Lancashire R, Herbison P, Wilson D, Grant A. Faecal incontinence and mode of first and subsequent delivery: a six-year longitudinal study. *BJOG* 2005; 112: 1075-82.
539. MacFaul GR, Chapman RW. Sclerosing cholangitis. *Curr Opin Gastroenterol* 2006; 22: 288-293.
540. Mack LA, Temple WJ. Education is the key to quality of surgery for rectal cancer. *Eur J Surg Oncol*. 2005; 31: 636-44.
541. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2007; 44: 265-7.
542. Maconi G, Bollani S, Bianchi Porro G. Ultrasonographic detection of intestinal complications in Crohn's disease. *Dig Dis Sci* 1996; 41: 1643-8.
543. Maconi G, Sampietro GM, Parente F, et al. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. *Am J Gastroenterol* 2003; 98: 1545-55.
544. Mahadevan U, Kane, S, Sandborn, W. J, Cohen, R. D, Hanson, K, Terdiman, J. P, and Binion, D. G. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. *Aliment.Pharmacol.Ther*. 2005; 21: 733-8.
545. Mahadevan U, Loftus E-VJ, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. *Am J Gastroenterol* 2002; 97: 910-4.
546. Mahadevan U, Marion JF, Present DH . Fistula response to methotrexate in Crohn's disease: a case series. *Aliment. Pharmacol. Ther*. 2003; 15 (18): 1003-8.

547. Mahadevan U, Sandborn, WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. *Gastroenterol* 2007; 133: 1106-12.
548. Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. *Inflamm Bowel Dis* 2005; 11: 395-9.
549. Maier AG, Funovics MA, Kreuzer SH, et al. Evaluation of perianal sepsis: comparison of anal endosonography and magnetic resonance imaging. *JMRI* 2001; 14: 254-60.
550. Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. *Gut* 1995, 37, 696-701.
551. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. *Lancet* 1998 14; 351: 805-6.
552. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterol* 1984; 86: 249-66.
553. Malchow H, Gertz B, CLAFOAM Study group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. *Aliment Pharmacol Ther* 2002; 16: 415-23.
554. Mallant-Hent RCh, Bodegraven AA van, Meuwissen SG, Manoliu RA. Alternative approach to massive gastrointestinal bleeding in ulcerative colitis: highly selective transcatheter embolization. *Eur J Gastroenterol Hepatol* 2003; 15: 189-93.
555. Marakhouski Y, Fixa B, Holoman J, Hulek P, Lukas M, Batovsky M, Rummyantsev VG, Grigoryeva G, Stolte M, Vieth M, Greinwald R; The International Salofalk Study Group. A double-blind dose-escalating trial comparing el mesalazine pellets with mesalazine tablets in active ulcerative colitis. *Aliment Pharmacol Ther*. 2005; 15 (21): 133-40.
556. Marcello PW, Milsom JW, Wong SK, Brady K, Goormastic M, Fazio VW. Laparoscopic total colectomy for acute colitis: a case-control study. *Dis Colon Rectum*. 2001; 44: 1441-5.
557. Marcello PW, Milsom JW, Wong SK, Hammerhofer KA, Goormastic M, Church JM, Fazio VW. Laparoscopic restorative proctocolectomy: case-matched comparative study with open restorative proctocolectomy. *Dis Colon Rectum*. 2000; 43: 604-8.
558. Marmo R, Rotondano G, Piscopo R, Bianco MA, Siani A, Catalano O, Cipolletta L.. Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn's disease: a prospective trial. *Clin Gastroenterol Hepatol* 2005; 3: 772-7.
559. Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE. Crohn's disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. *Radiology* 2006; 238: 128-34.
560. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. *Gut*. 1997; 40: 775-81.
561. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. *Gut*. 2005; 54: 960-5.

562. Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. *Aliment Pharmacol Ther* 1998; 12: 1101-8.
563. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2004; 10: 352-6.
564. Mayberry JF. The diagnosis of inflammatory bowel disease-What should we tell the patient? *Ital J Gastroenterol Hepatol* 1997; 29:483-6.
565. Mayberry MK, Probert C, Srivastava E, Rhodes J, Mayberry JF. Perceived discrimination in education and employment by people with Crohn's disease: a case control study of educational achievement and employment. *Gut* 1992; 33: 312-4.
566. Mazzeo S, Caramella D, Battolla L, et al. Crohn disease of the small bowel: spiral CT evaluation after oral hyperhydration with isotonic solution. *J Comput Assist Tomogr*. 2001; 25: 612-6.
567. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JD, Lerebours E, Hecketsweiler P, Galmiche JP, Colin R. Controlled trial of bowel rest in the treatment of severe acute colitis. *Gut*, 1986; 27: 481-5.
568. McCall TB, O'Leary D, Bloomfield J, O'Morain CA. Therapeutic potential of fish oil in the treatment of ulcerative colitis. *Aliment Pharmacol Ther*, 1989; 3: 415-24.
569. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2005; 2: CD000297.
570. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2004; 4: CD004722.
571. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2004; 18: CD 004722.
572. McKee RF, Keenan RA, Munro A. Colectomy for acute colitis: is it safe to close the rectal stump? *Int J Colorectal Dis* 1995; 10: 222-4.
573. McKinnie, V, Swift, S. E, Wang, W, Woodman, P, O'Boyle, A, Kahn, M, Valley, M, Bland, D, and Schaffer, J. The effect of pregnancy and mode of delivery on the prevalence of urinary and fecal incontinence. *Am.J Obstet Gynecol*. 2005; 193: 512-7.
574. McNamara M. Surgical treatment of enterovesical fistulas in Crohn's disease. *Dis Colon Rectum* 1990; 33: 271-6.
575. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. *Hum Pathol* 1989; 20: 1008-14.
576. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. *Isr Med Assoc J* 2004; 6: 88-90.
577. Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G and Pacini F. *Sand J Gastroenterol*, 1996; 31: 267-72.
578. Miao YM, Koh DM, Amin Z, et al. Ultrasound and magnetic resonance imaging assessment of active bowel segments in Crohn's disease. *Clinical Radiology* 2002; 57: 913-8.

579. Michelassi F, Hurst RD, Melis M, Rubin M, Cohen R, Gasparitis A, Hanauer SB, Hart J. Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. *Ann Surg*. 2000, Sep; 232: 401-8.
580. Michelassi F, Melis M, Rubin M, Hurst RD. Surgical treatment of anorectal complications in Crohn's disease. *Surgery* 2000; 128 (4), 597-603.
581. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease. *J Surg Res* 2004; 117: 71-8.
582. Middleton SJ, Li D, Wharton S, et al. Validation of 99Tc-HMPAO leucocyte scintigraphy in ulcerative colitis by comparison with histology. *Brit J Radiol* 1995; 68: 1061-6.
583. Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebocontrolled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *Aliment Pharmacol Ther* 2002; 16: 1131-5.
584. Miehsler W, Puspok A, Oberhuber T, Vogelsang H. Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract. *Inflamm Bowel Dis* 2001; 7: 99-105.
585. Miller GV, Finan PJ. Flap advancement and core fistulectomy for complex rectal fistula. *Br.J.Surg*. 1998, 85 (1), 108-10.
586. Miller L, Caton S, Lynch D. Telephone clinic improves quality of follow-up care for chronic bowel disease. *Nurs Times* 2002; 98 (31): 36-8.
587. Miller TS. From illness comes strength. A nursing student with Crohn's disease tells her story. *Imprint* 2001; 48: 45-75.
588. Milsom JW, Hammerhofer KA, Böhm B, et al. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic crohn's disease. *Dis Colon Rectum* 2001; 44: 1-9.
589. Mimura T, Rizello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Gioncetti P, Campieri M and Kamm MA. Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis. *Gut*, 2004; 53: 108-14.
590. Minderhoud IM, Oldenburg B, Van Dam S, Berge Henegouwen GP van. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. *Amer J Gastroenterol* 2003; 98: 1088-93.
591. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. *Dig Dis Sci* 2004; 49: 469-74.
592. Mingrone G, Capristo E, Greco AV, Benedetti G, De Gaetano A, Tataranni PA, Gasbarrini G. Elevated diet-induced thermogenesis and lipid oxidation rate in Crohn disease. *Am J Clin Nutr*. 1999; 69: 325-30.
593. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. *Inflammatory Bowel Diseases* 2004; 10: 135-9.
594. Mitchell SA, Bansi DS, Hunt N, Von BK, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. *Gastroenterol* 2001; 121: 900-7.
595. Mittermaier C, Dejaco C, Waldhoer T, Oefflerbauer-Ernst A, Miehsler W, Beier M, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-month follow-up study. *Psychosomatic Medicine* 2004; 66: 79-84.

596. Mizrahi N, Wexner SD, Zmora O, Da-Silva G, Efron J, Weiss EG, et al. Endorectal advancement flap: are there predictors of failure? *Dis.Colon Rectum* 2002; 45(12): 1616-21.
597. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. *Gastroenterol* 1990; 98: 811-8.
598. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. *Gastroenterol* 1981; 80: 72-6.
599. Mólnar T, Papós M, Gyulai C, et al. Clinical value of technetium 99m-HMPAO-labeled leucocyte scintigraphy and spiral computed tomography in active Crohn's disease. *Am J Gastroenterol* 2001; 96: 1517-21.
600. Monkemuller K, Weigt J, Treiber G, et al. Diagnostic and therapeutic impact of doubleballoon enteroscopy. *Endoscopy* 2006; 38: 67-72.
601. Moody GA, Jayanihi V, Probert CSJ, Makay H, Mayberry JF. Longterm therapy with sulfasalazine protects against colorectal cancer in ulcerative colitis. *Eur J Gastroenterol Hepatol* 1996; 8: 1179-93.
602. Moody GA, Mayberry JF. Life insurance and inflammatory bowel disease: is there discrimination against patients? *Int J Colorectal Dis* 1996; 11: 276-8.
603. Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. *Int J Colorectal Dis* 1997; 12: 220-4.
604. Moody GA, Probert CSJ, Jayanthi V, Mayberry JF. The attitude of employers to people with inflammatory bowel disease. *Soc Sct Med* 1992; 34: 459-60.
605. Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S. Cyclosporine excretion into breast milk. *Transplantation* 2003; 75: 2144-6.
606. Morson BC, Pang LS. Rectal biopsy as an aid to cancer control in ulcerative colitis. *Gut* 1967; 8: 423-34.
607. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel disease patients. *Am J Gastroenterol* 2004; 99: 656-61.
608. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after ciclosporine-induced remission of severe ulcerative colitis. *Clin Gastroenterol Hepatol* 2006; 4: 760-5.
609. Moum B, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. *Gut* 1997; 40: 328-32.
610. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. *Eur J Gastroenterol Hepatol* 1996; 8: 549-53.
611. Mulder CJ, Tytgat GN, Wiltink EH, Houthoff HJ. Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial. *Scand J Gastroenterol* 1988; 23: 1005-8.

612. Mulder CJ, van den Hazel SJ. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. *Mediators Inflamm* 1998; 7: 135-6.
613. Munkholm Larsen P, Rasmussen D, Rønn B, Munck O, Elmgreen J, Binder V. Elemental diet: A therapeutic approach in chronic inflammatory bowel disease. *J Intern Med* 1989; 225: 325-31.
614. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. *Scand J Gastroenterol* 1992; 27: 609-14.
615. Munkholm P. Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. *Dan Med Bull* 1997; 44: 287-302.
616. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a ciclosporine-treated mother. *Obstet.Gynecol.* 2001; 97: 816-8.
617. Munoz-Juarez M, Yamamoto T, Wolff BG, Keighley MR. Wide-lumen stapled anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn's disease. *Dis Colon Rectum* 2001; 44: 20-5; discussion 25-6.
618. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. *Ophthalmology* 2004; 111: 352-356.
619. Mussell M, Bocker U, Nagel N, Singer MV. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2004; 16: 1273-80.
620. Mylonakis E, Allan RN, Keighley MR. How does pouch construction for a final diagnosis of Crohn's disease compare with ileoproctostomy for established Crohn's proctocolitis? *Dis Colon Rectum* 2001; 44: 1137-42; discussion 1142-3.
621. Myrelid P, Andersson P, Sjö Dahl R, Olaison G. Immunosuppression for Crohn's disease is associated with increased frequency of anastomotic complications. *Colorectal Disease* 2004; 6: 26.
622. Naber AH, Jong DJ de. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. *Neth J Med.* 2003; 61: 105-10.
623. Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. *J Clin Gastroenterol* 1989; 11: 403-6.
624. Nelis, G. F. Diarrhoea due to 5-aminosalicylic acid in breast milk [letter]. *Lancet* 1989; 1: 383.
625. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. *JAMA* 2002; 288: 872-81.
626. Nessar G, Fazio VW, Tekkis P, Connor J, Wu J, Bast J, Borkowski A, Delaney CP, Remzi FH. Long-term outcome and quality of life after continent ileostomy. *Dis Colon Rectum* 2006; 49: 336-44.
627. Neye H, Voderholzer W, Rickes S, Weber J, Wermke W, Lochs H. Evaluation of criteria for the activity of Crohn's disease by power Doppler sonography. *Dig Dis* 2004; 22: 67-72.
628. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. *Inflamm Bowel Dis.* 2007; 13: 129-34.
629. Ng RL, Davies AH, Grace RH, Mortensen NJ. Subcutaneous rectal stump closure after emergency subtotal colectomy. *Br J Surg.* 1992; 79: 701-3.

630. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. *Scand.J.Gastroenterol* 1983; 18: 735-42.
631. Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease. *Scand.J.Gastroenterol* 1984; 19: 724-32.
632. Nightingale AJ, Middleton W, Middleton SJ, Hunter JO. Evaluation of the effectiveness of a specialist nurse in the management of inflammatory bowel disease (IBD). *Eur J Gastroenterol Hepatol* 2000; 12: 967-73.
633. NIPO enquete CCUVN. Uit: Op eigen kracht resultaten onderzoeken onder patiënten met de ziekte van Crohn of Colitis Ulcerosa van E. van der Storm 2007.
634. Quan H, Present JW, Sutherland LR, Evaluation of Educational Programs in Inflammatory Bowel Disease. *Crohn's & Colitis Foundation of America*: 2003; IBD 9: 356-362.
635. Norgard, B, Czeizel, A. E, Rockenbauer, M, Olsen, J, and Sorensen, H. T. Populationbased case control study of the safety of sulfasalazine use during pregnancy. *Aliment.Pharmacol.Ther.* 2001; 15: 483-6.
636. Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. *Gut* 2003a; 52: 243-7.
637. Norgard B, Fonager K, Sorensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. *Am J Gastroenterol* 2000; 95: 3165-70.
638. Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. *Am.J Gastroenterol* 2007; 102: 1406-13.
639. Norgard B, Puho E, Pedersen L, Czeizel AE, Sorensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. *Am J Gastroenterol* 2003b; 98: 2006-10.
640. North CS, Alpers DH. A review of studies of psychiatric factors in Crohn's disease: Etiologic implications. *Ann Clinical Psychiatry* 1994; 6: 117-24.
641. Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. *Am J Gastroenterol* 1989; 84: 249-54.
642. Nwokolo CU, Tan, WC, Andrews, HA, Allan, RN. Surgical resections in parous patients with distal ileal and colonic Crohn's disease. *Gut* 1994; 35: 220-223.
643. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with ciclosporine. *Transplantation* 1998; 65: 253-5.
644. Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn's disease. *Virchows Arch.* 1998; 432: 49-52.
645. Oberhuber G, Püspök A, Oesterreicher C, Novacek G, Zauner C, Burghuber M, et al. Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease. *Gastroenterology.* 1997; 112: 698-706.
646. Oca J de, Sanchez-Santos R, Rague JM, et al. Long-term results of ileal pouch-anal anastomosis in Crohn's disease. *Inflamm Bowel Dis* 2003; 9: 171-5.
647. Odze RD, Farraye FA, Hecht JL, Hornick J. Long term outcome confirms that polypectomy is an adequate treatment for adenoma-like DALMs in ulcerative colitis. *Clinical Gastroenterol Hepatol* 2004; 2: 534-41.



648. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut*. 2006; 55: 1255-62.
649. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001; 411: 603-6.
650. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. *Clin Gastroenterol Hepatol* 2006; 4: 6-10.
651. Olaison G, Sjødahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. *Gut* 1990; 31: 325-8.
652. Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? *Am J Gastroenterol* 2000; 95: 2825-30.
653. Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Iron and inflammatory bowel disease. *Aliment Pharmacol Ther*. 2001; 15: 429-38.
654. Oldenburg B, Berge Henegouwen GP van, Rennick D, Asbeck BS van, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. *Eur J Clin Invest*. 2000; 30: 505-10.
655. Oldenburg B, Tuyl BA van, Griend R van der, Fijnheer R, Berge Henegouwen GP van. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. *Dig Dis Sci*. 2005; 50: 235-40.
656. Olsen KØ, Juul S, Berndtsson I, Öresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. *Gastroenterol* 2002; 122: 15-9.
657. Olsson R, Danielsson A, Järnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. *Gastroenterol* 1991; 100: 1319-23.
658. Oostayen JA van, Wasser MNJM, Griffioen G, Van Hoogezand RA, Lamers CBHW, De Roos A. Diagnosis of Crohn's ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow. *Am J Gastroenterol* 1998; 93: 88-91.
659. Oostenbrug LE, Dulleman HM van, Meerman GJ te, Jansen PL. IBD and genetics: new developments. *Scand J Gastroenterol Suppl* 2003;(239):63-8.
660. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. *Gastroenterol* 2002; 123: 714-8.
661. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut* 1998; 42: 387-91.
662. Orholm, M, Binder, V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. *Scand.J.Gastroenterol* 2000; 35: 1075-81.
663. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosentino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone

- M; Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. *Dig Liver Dis.* 2005; 37: 577-83.
664. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. *Br J Surg* 1999; 86: 360-4.
665. Oshitani N, Yukawa T, Yamagami H, Inagawa M, Kamata N, Watanabe K, Jinno Y, Fujiwara Y, Higuchi K, Arakawa T. Evaluation of deep small bowel involvement by double-balloon enteroscopy in Crohn's disease. *Am J Gastroenterol* 2006; 101: 1484-9.
666. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. *J Reumatol.* 2000; 27: 1872-5.
667. Ostensen M, Motta M. Therapy insight: the use of antireumatic drugs during nursing. *Nat Clin Pract Rheumatol* 2007; 3: 400-6.
668. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2005; : CD000296.
669. Ozuner G, Fazio VW, Lavery IC, Church JM, Hull TL. How safe is stricturoplasty in the management of Crohn's disease? *Am J Surg.* 1996; 171: 57-60; discussion 60-1.
670. Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. *Dis Colon Rectum.* 1996; 39: 10-4.
671. Ozuner G, Strong SA, Fazio VW. Effect of rectosigmoid stump length on restorative proctocolectomy after subtotal colectomy. *Dis Colon Rectum.* 1995; 38: 1039-42.
672. Pahlman L, Gunnarsson U, Karlbom U. The influence on treatment outcome of structuring rectal cancer care. *Eur J Surg Oncol.* 2005; 31: 645-9.
673. Pallotta N, Tomei E, Viscido A, et al. Small intestine contrast ultrasonography. An alternative to radiology in the assessment of small bowel disease. *Inflamm Bowel Dis* 2005; 11: 146-53.
674. Palm Ø, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. *J Reumatol.* 2005; 32: 1755-9.
675. Palm Ø, Moum B, Jahnsen J, Gran JT. Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. *J Reumatol* 2001; 28: 590-594.
676. Panis Y, Poupard B, Nemeth J, et al. Ileal pouch/anal anastomosis for Crohn's disease. *Lancet* 1996; 347: 854-7.
677. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. *Aliment Pharmacol Ther* 2002; 16: 1751-9.
678. Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso L. Long-term outcome of Crohn's disease following corticosteroid-induced remission. *Am J Gastroenterol* 2007; 102: 814-9.
679. Papós M, Nagy F, Nárai G, et al. Anti-granulocyte immunoscintigraphy and <sup>99m</sup>Tc Hexamethylpropyleneamine-Oxime-labeled leukocyte scintigraphy in inflammatory bowel disease. *Dig Dis Sci* 1996; 41: 412-20.

680. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. *Pediatrics* 2006; 118: 1950-61.
681. Pardi DS, Loftus EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterol* 2003; 124: 889-93.
682. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK and Gostout CJ. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. *Gastrointest Endosc* 1999; 49: 153-7.
683. Pardi DS, Tremaine W, Sandborn W, et al. Renal and urologic complications of inflammatory bowel disease. *Am J Gastroenterol* 1998; 93: 504-14.
684. Parente F, Cucino C, Bollani S, Imbesi V, Maconi G, Bonetto S, Vago L, Porro GB. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role. *Am J Gastroenterol* 2000; 95: 705-11.
685. Parente F, Greco S, Molteni M, et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, x-ray studies, and ileocolonoscopy. *Gut* 2004; 53: 1652-7.
686. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. *Hepatology* 2007; 45: 1267-74.
687. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. *Gastroenterol* 2002; 123: 707-13.
688. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. *Ann Intern Med* 1995; 122: 132-42.
689. Peeters, M, Nevens, H, Baert, F, Hiele, M, de Meyer, A. M, Vlietinck, R, and Rutgeerts, P. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. *Gastroenterol* 1996; 111: 597-603.
690. Perkins KA, Benowitz N, Henningfield J, Newhouse P. Society for Research on Nicotine and Tobacco: A conference summary. *Addiction* 1996; 91: 129-37.
691. Peters F, Albersnagel F, Reitsma B. Maag-, Darm-, en Leveraandoeningen. In G Pool, F Heuvel, AV Ranchor en R Sanderman (Red.), *Handboek Psychologische Interventies bij Chronisch-Somatische Aandoeningen*. Assen: Van Gorcum, 2004.
692. Pica RPO, Iacopini F, Marcheggiano A, Crispino P, Rivera M, Bella A, Consolazio A, Paoluzi P. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. *Inflamm Bowel Dis* 2004; 10: 731-6.
693. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992; 37: 1396-1403.
694. Pinczowski D, Ekbohm A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. *Gastroenterol* 1994; 107: 117-20.
695. Podolsky DK. Inflammatory bowel disease. *N Engl J Med* 2002; 347: 417-9.
696. Poggioli G, Laureti S, Pierangeli F, Ugolini F. A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis: side-to-side diseased to disease-free anastomosis. *Dis Colon Rectum* 2003; 46: 127-30.
697. Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a

- double-blind, randomized, placebo-controlled study. *Aliment Pharmacol Ther* 2000; 14: 1191-8.
698. Polifka, J. E. and Friedman, J. M. Teratogen update: azathioprine and 6mercaptopurine. *Teratology* 2002; 65: 240-61.
699. Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA. Recurrence after segmental resection for colonic Crohn's disease. *Br J Surg.* 2005; 92: 1143-9.
700. Polle SW, Vlug MS, Slors JF, Zwinderman AH, Hoop AG van der, Cuesta MA, Gouma DJ, Bemelman, WA. Effect of vaginal delivery on long-term pouch function. *Br.J.Surg.* 2006; 93: 1394-1401.
701. Polle SW, Wind J, Ubbink DT, Hommes DW, Gouma DJ, Bemelman WA. Short-term outcomes after laparoscopic ileocolic resection for Crohn's disease. A systematic review. *Dig Surg.* 2006; 23 (5-6): 346-57.
702. Ponsioen CIJ, Tytgat GNJ. Primary sclerosing cholangitis: a clinical review; *Am J Gastor-Enterol* 1998; 93: 515-23.
703. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. *Dis.Colon Rectum* 2002, 45, 771-5.
704. Post S, Herfarth C, Bohm E, Timmermanns G, Schumacher H, Schurmann G, Golling M. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. *Ann Surg.* 1996; 223: 253-60.
705. Pounder RE. Measles virus and Crohn's disease: research from the Royal Free Hospital in London. *J Gastroenterol* 1995; 30 Suppl 8: 48-51.
706. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. *New Eng J of Med* 2005; 352: 2184-92.
707. Pradel JA, David XR, Taourel P, Djafari M, Veyrac M, Bruel J-M. Sonographic assessment of the normal and abnormal bowel wall in nondiverticular ileitis and colitis. *Abdom Imaging* 1997; 22: 167-72.
708. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with *Lactobacilles GC*. *Gut*, 2002; 51: 405-9.
709. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DG, Pasternack BS. Treatment of Crohn's disease with 6 Mercaptopurine. A long term randomized double blind study. *N Engl J Med* 1980; 302: 981-7.
710. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Hogezaand RA van, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med.* 1999; 340: 1398-405.
711. Present DH. Toxic megacolon. *Med Clin North Am* 1993, 77: 1129-48.
712. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease-colitis indeterminate. *J Clin Pathol* 1978; 31: 567-77.
713. Provenzale D, Wong JB, Onken JE, Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. *Am J Gastroenterol* 1998; 93: 872-80.
714. Prudhomme M, Dozois RR, Godlewski G, Mathison S, Fabbro-Peray P. Anal canal strictures after ileal pouch-anal anastomosis. *Dis Colon Rectum.* 2003; 46: 20-3.

715. Puhakka KB, Jurik AG, Schiottz-Christensen B, et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. *Scand J Rheumatol* 2004; 33: 332-8.
716. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, et al. Transdermal nicotine for active ulcerative colitis. *N Engl J Med*. 1994; 330: 811-5.
717. Pullan RD. Colonic mucus, smoking and ulcerative colitis. *Ann R Coll Surg Engl* 1996; 78: 85-91.
718. Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. *Scand J Gastroenterol* 2007; 42: 194-9.
719. Quan H, Present JW, Sutherland LR, Evaluation of Educational Programs in Inflammatory Bowel Disease. *Crohn's & Colitis Foundation of America: IBD* 9: 356-362.
720. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. *Hepatology*. 1990; 11: 7-11.
721. Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology*. 2004; 126: 402-13.
722. Radlmayr M, Török HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. *Gastroenterol* 2002; 122: 2091-2.
723. Rankin GB, Watts HD, Melnyk CS, Kelley ML, Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. *Gastroenterol* 1979; 77: 914-920.
724. Rannem T, Ladefoged K, Hylander E, Hegnhøj J, Jarnum S. Selenium status in patients with Crohn's disease. *Am J Clin Nutr*. 1992; 56: 933-7.
725. Ratzinger G, Sepp N, Vogetseder W, Tilg H. Cheilitis granulomatosa and Melkersson-Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients. *J Eur Acad Dermatol Venereol*. 2007; 21: 1065-70.
726. Ravid, A, Richard, C. S, Spencer, L. M, O'Connor, B. I, Kennedy, E. D, MacRae, H. M, Cohen, Z, and McLeod, R. S. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. *Dis.Colon Rectum* 2002; 45: 1283-8.
727. Read AM, Mayberry JF. Doctor or nurse? The patients' choice. *Postgrad Med J* 2000; 76: 212-4.
728. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. *Am J Gastroenterol* 2006; 101: 2410-22.
729. Regimbeau JM, Panis Y, Pocard M, et al. Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease. *Dis Colon Rectum* 2001; 44: 769-78.

730. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. *Inflamm Bowel Dis* 2003; 9: 98-103.
731. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. *Amer J Gastroenterol* 2003; 98: 1821-6.
732. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. *Br J Dermatol* 1998; 139: 755-7.
733. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. *J Am Acad Dermatol* 2005; 53: 273-83.
734. Reilly WT, Pemberton JH, Wolff BG, Nivatvongs S, Devine RM, Litchy WJ, McIntyre PB. Randomized prospective trial comparing ileal pouch-anal anastomosis performed by excising the anal mucosa to ileal pouch-anal anastomosis performed by preserving the anal mucosa. *Ann Surg*. 1997; 225: 666-76; discussion 676-7.
735. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclooxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. *Alimentary Pharmacol Therapeutics* 2003; 17: 1371-1380.
736. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non-pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet*, 1999; 354: 635-9.
737. Remzi FH, Fazio VW, Delaney CP, Preen M, Ormsby A, Bast J, O'Riordain MG, Strong SA, Church JM, Petras RE, Gramlich T, Lavery IC. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years.
738. Rennie JS, Reade PC, Hay KD, Scully C. Recurrent aphthous stomatitis. *Br Dent J* 1985; 159: 361-7.
739. Repiso A, Alcantara M, Munoz-Rosas C, et al. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. *Rev Esp Enferm Dig* 2006; 98: 510-7.
740. Requena L, Requena C. Erythema nodosum. *Dermatol Online J* 2002; 8: 4.
741. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. *Am J Gastroenterol* 2001; 96: 722-9.
742. Ricart E, Panaccione R, Loftus EV, Jr., et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a casecontrol study. *Inflamm Bowel Dis* 2004; 10: 207-214.
743. Richards M, Hardy R, Wadsworth ME. Long-term effects of breast-feeding in a national birth cohort: educational attainment and midlife cognitive function. *Public Health Nutr*. 2002; 5: 631-5.
744. Richter-Hintz D, Schuppe HC, Homey B, Lehmann P, Ruzicka T. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. *J Am Acad Dermatol* 2000; 42 (2 Pt 1): 304-5.
745. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* 1983; 14: 931-968.

746. Rieber A, Aschoff A, Nüssle K, et al. MRI in the diagnosis of small bowel disease: use of positive and negative oral contrast media in combination with enteroclysis. *Eur Radiol* 2000; 10: 1377-82.
747. Riegler G, D'Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. *Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol* 1998; 33: 93-98.
748. Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandal BK, Turnberg LA. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. *Gut* 1987; 28: 1008-12.
749. Riordan AM, Hunter JO, Cowan RE, Crompton JR, Davidson AR, Dickinson RJ, Dronfield MW, Fellows IW, Hishon S, Kerrigan GN, et al. Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. *Lancet*. 1993; 342: 1131-4.
750. Rispo A, Imbriaco M, Celentano L, et al. Noninvasive diagnosis of small bowel Crohn's disease: combined use of bowel sonography and Tc-99m-HMPAO leukocyte scintigraphy. *Inflamm Bowel Dis* 2005; 11: 376-82.
751. Rispo A, Imbriaco M, Celentano L, et al. Small bowel Crohn's disease: comparison of enteroclysis, bowel sonography and Tc-99m-HMPAO leukocyte scintigraphy. *Eur Rev med Pharmacol Sci*. 2004; 8: 219-24.
752. Robinson A, Bokemeyer S, Cripps G, Frieri E, Langholz M, Lindholm R, Mitchell A, Trachter S, Travis AA, van Bodegraven, and Kane S. Towards better patient compliance in IBD: Report of an international compliance consensus meeting. *BMJ Gastroenterology & Hepatology* 2005; 1: 206-15.
753. Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. *Gastroenterol* 1998; 115: 36-41.
754. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2006; 18: CD004826.
755. Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. *Am J Gastroenterol* 2001; 96: 2143-9.
756. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. *Semin Hematol* 1997; 34: 171-87.
757. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. *Gastroenterol* 1985; 89: 1342-46.
758. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. *Scand J Gastroenterol* 1999; 34: 50-4.
759. Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn's disease. *Surg Endosc*. 2005; 19: 1549-55.
760. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol* 2006; 12: 4819-31.

761. Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellmann DB. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. *Semin.Arthritis Rheum.* 1988; 18: 88-110.
762. Rowlinson A. Inflammatory bowel disease. 3: importance of partnership in care. *Br J Nurs* 1999; 8 (15): 1013-8.
763. Roy MA. Inflammatory bowel disease. *Surg Clin North Am* 1997, 77: 1419-31.
764. Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN. Total enteral nutrition support improves body composition of patients with active Crohn's disease. *J Parenter Enteral Nutr.* 1995; 19: 95-9.
765. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. *Gastroenterol* 1999; 117: 1295-1300.
766. Russel MGVM, Ryan BM, Dagnelie PC, De RM, Sijbrandij J, Feleus A, et al. Insurance problems among inflammatory bowel disease patients: Results of a Dutch population based study. *Gut* 2003; 52: 358-62.
767. Russel MGVM, Volovics A, Schoon EJ, et al. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. *Inflamm Bowel Dis* 1998; 4: 182-6.
768. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezaand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology.* 1999; 117: 761-9.
769. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology.* 2004; 126: 402-13.
770. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterol* 1990; 99: 956-63.
771. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. *Gastroenterology.* 1995; 108: 1617-21.
772. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. *N Engl J Med* 1994; 331: 842-5.
773. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2005; 353: 2462-76.
774. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebocontrolled trial. *Gastroenterology.* 2005; 128: 856-61.
775. Rutter MD, Saunders BP, Schofield G, et al. Pancolic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. *Gut* 2004; 53: 256-60.
776. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterol* 2006; 130: 1030-



38.

777. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endocopies appearances help to predict cancer risk. *Gut* 2004; 53: 1813-6.
778. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. *Gastrointest Endosc* 2004; 60 : 334-9.
779. Rutter MD, Saunders BP, Wilkinson KH, Rumbles Schoffeld G, Kemm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasias in ulcerative colitis. *Gastroenterology* 2004; 126: 451-9.
780. Ryan WR, Ley C, Allan RN, Keighley MR. Patients with Crohn's disease are unaware of the risks that smoking has on their disease. *J Gastrointest Surg* 2003; 7: 706-11.
781. Ryan BM, Russel MG, Langholz E, Stockbrugger RW. Aminosalicylates and colorectal cancer in IBD: a not so bitter pill to swallow. *Am J Gastroenterol* 2003; 96: 1682-7.
782. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. *Am J Gastroenterol* 1997; 92: 1867-71.
783. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. *Dis Colon Rectum* 1996; 39: 893-8.
784. Sahai A, Belair M, Gianfelice D, Cote S, Gratton J, Lahaie R. Percutaneous drainage of intra-abdominal abscesses in Crohn's disease: short and long-term outcome. *Am J Gastroenterol* 1997; 92: 275-8.
785. Sahnoud T, Hochtin-Boes G, Modigliani R, Bitoun A, Colombel JF, Soule JC, Florent C, Gendre JP, Lerebours E, Sylvester R. Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. *Gut* 1995; 37: 811-8.
786. Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, Meucci G, Spina L, de Franchis R. Low vitamin B plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. *Am J Gastroenterol* 2003; 98: 112-7.
787. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K and Okada M. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. *JPEN*, 2002; 26: 98-103.
788. Salomon P, Kornbluth AA,owitz HD/ Treatment of ulcerative colitis with fish oil n-3 fatty acid: an open trial. *J Clin Gastroenterol*, 1990; 12: 157-61.
789. Sampietro GM, Sartani A, Danelli P, et al. [Strictureplasty in the surgical treatment of complicated Crohn's disease]. *Ann Ital Chir* 2003; 74: 659-63.
790. Sandborn WJ, Feagan BG, Hanauer SB, et al Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. *Gastroenterol* 2001; 120: 1330-8.
791. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. *Gut* 2004; 53: 1485-93.

792. Sandborn WJ, Hanauer SB, Rutgeerts PJ, Fedorak RN, Lukas M, Macintosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial. *Gut* 2007; 56: 1232-9.
793. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. *Am J Gastroenterol* 2002; 97: 2962-72.
794. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. *Am J Gastroenterol* 2005; 100: 1780-7.
795. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. *Gastroenterol* 2003; 125: 380-8.
796. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, d'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. A randomized trial. *Ann Intern Med*. 2007; 146: 829-38.
797. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. *Clin Gastroenterol Hepatol* 2006; 4: 203-211.
798. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1997; 126: 364-71.
799. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of ciclosporine enemas for mildly to moderately active left-sided ulcerative colitis. *Gastroenterology*. 1994; 106: 1429-35.
800. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. *Am J Gastroenterol* 1997; 92: 876-9.
801. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004; 350: 876-85.
802. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. *Clin Gastroenterol Hepatol* 2004; 2: 912-20.
803. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. *Gastroenterol* 2004; 126: 1518-32.
804. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006; 55: 749-53.
805. Sau, A, Clarke, S, Bass, J, Kaiser, A, Marinaki, A, and Nelson-Piercy, C. Azathioprine and breastfeeding: is it safe? *BJOG*. 2007; 114: 498-501.
806. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. *Reumatology (Oxford)* 2006; 45: 982-9.

807. Scarpa M, Angriman I, Barollo M, et al. Role of stapled and hand-sewn anastomoses in recurrence of Crohn's disease. *HepatoGastroenterol* 2004; 51: 1053-7.
808. Schiller MR, Miller M, Moore C, Davis E, Dunn A, Mulligan K, Zeller P. Patients report positive nutrition counseling outcomes. *J Am Diet Assoc* 1998; 98: 977-84.
809. Schilstra P. Zorg op afstand. Onderzoek onder patiënten met de ziekte van Crohn/colitis ulcerosa naar de tevredenheid met een nieuwe manier van zorgverlening vanuit de Afdeling Maag-, Darm- en Leverziekten van het Academisch Ziekenhuis Groningen. Groningen, Wetenschapswinkel Geneeskunde en Volksgezondheid, 2004.
810. Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. *Dis Colon Rectum* 2007; 50: 1697-706.
811. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. *Gastroenterol* 2000; 119: 1203-8.
812. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. *Clin Gastroenterol Hepatol* 2005; 3: 113-21.
813. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? *Gut*. 2001; 48: 473-7. Comment in: *Gut*. 2001; 48: 448.
814. Schoon EJ, van-Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl* 2000; 232: 43-47.
815. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, Lochs H, Raedler A. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease: *N Engl J Med* 1996; 334: 619-23.
816. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OÅ, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. *Gastroenterology*. 2005 Sep; 129: 807-18. Erratum in: *Gastroenterology*. 2005; 129: 1808. dosage error in text. Comment in: *Gastroenterol* 2005; 129: 1114-6. *Gastroenterol* 2006; 130: 285-6; author reply 286. *Inflamm Bowel Dis* 2006; 12: 249.
817. Schreyer AG, Gölder S, Scheibl K, et al. Dark lumen magnetic resonance enteroclysis in combination with MRI colonography for whole bowel assessment in patients with Crohn's disease: first clinical experience. *Inflamm Bowel Dis* 2005; 11: 388-94.
818. Schreyer AG, Rath HC, Kikinis R, et al. Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease; a feasibility study. *Gut* 2005; 54: 250-6.
819. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S,ge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. *Am J Gastroenterol* 2005; 100: 2503-9.

820. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. *Am J Gastroenterol* 2000; 95 (1 Suppl): S19-21.
821. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. *Lactobacillus GG* in inducing and maintaining remission of Crohn's disease. *BMC Gastroenterol* 2004, 15; 4: 5.
822. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. *Gastroenterol* 2002; 122: 875-80.
823. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. *Gastroenterol* 2001; 121: 1064-72.
824. Schwartz SP, Blanchard EB, Berreman CF, Scharff L. Psychological aspects of irritable bowel syndrome: Comparisons with inflammatory bowel disease and nonpatient controls. *Behaviour Research and Therapy* 1993; 31: 297-304.
825. Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn's fistulas. *Dis.Colon Rectum* 1996, 39, 1039-43.
826. Scott NA, Hughes LE. Timing of ileocolonic resection for symptomatic Crohn's disease-the patient's view. *Gut* 1994; 35: 656-7.
827. Scott NA, Sue-Ling HM, Hughes LE. Anastomotic configuration does not affect recurrence of Crohn's disease after ileocolonic resection. *Int J Colorectal Dis* 1995; 10: 67-9.
828. Searle A, Bennett P. Psychological factors and inflammatory bowel disease: A review of a decade of literature. *Psychology, Health and Medicine* 2001; 6: 121-35.
829. Selby W. The natural history of ulcerative colitis. *Bailliere's Clinical Gastroenterol* 1997; 11: 53-64.
830. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2003; 18: 191-8.
831. Shatari T, Clark MA, Yamamoto T, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease. *Colorectal Dis* 2004; 6: 438-41.
832. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. *Aliment Pharmacol Ther* 2005 15; 22: 721-8.
833. Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Brzezinski A, Oikonomou I, Sherman KK, Lashner BA. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. *Dis Colon Rectum*. 2007; 50: 498-508.
834. Sheridan MB, Nicholson DA, Martin DF. Transabdominal ultrasonography as the primary investigation in patients with suspected Crohn's disease or recurrence: a prospective study. *Clin Radiol* 1993; 48: 402-4.
835. Sheth SG, LaMont JT. Toxic megacolon. *Lancet* 1998; 351: 509-12.
836. Shetty K, Rybicki L, Brzezinski A, Cary WD, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1999; 94: 1643-9.
837. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. *Cochrane Database Syst Rev*. 2005 25; : CD 004277. *Cochrane Database Syst Rev*. 2005 25; : CD 004277. Review.

838. Shield DE, Lytton B, Weiss RM, Schiff M. Urologic complications of inflammatory bowel disease. *J Urol* 1976; 115: 701-6.
839. Shim YW, Suh JS. Primary hypertrophic osteoarthropathy accompanied by Crohn's disease: a case report. *Yonsei Med J* 1997; 38: 319-22.
840. Shoenut JP, Semelka RC, Magro CM, et al. Comparison of magnetic resonance imaging and endoscopy in distinguishing the type and severity of inflammatory bowel disease. *Clin J Gastroenterol* 1994; 19: 31-5.
841. Shore G, Gonzalez QH, Bondora A, et al. Laparoscopic vs conventional ileocelectomy for primary Crohn disease. *Arch Surg* 2003; 138: 76-79.
842. Siddiqui U, Denise PD. Flexible sigmoidoscopy and colonoscopy during pregnancy. *Gastrointest.Endosc.Clin.N.Am.* 2006; 16: 59-69.
843. Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. *Clin Gastroenterol Hepatol* 2005; 3: 122-32.
844. Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. *Inflamm Bowel Dis.* 2005; 11: 707-12.
845. Silva AD de, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. *Inflamm Bowel Dis.* 2003; 9: 316-20.
846. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. *J Intern Med.* 1996; 240: 285-92.
847. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995; 37: 71-76.
848. Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein ChN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, ea. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol Vol* 19, suppl.A, 2005.
849. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease (Cochrane Review). *Cochrane Database Syst Rev.* 2001; : CD002913.
850. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. *Am J Gastroenterol* 2002; 97: 389-96.
851. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. *J Clin Gastroenterol* 2005; 39: 284-90.
852. Skalej M, Makowiec F, Weinlich M, et al. Magnetic resonance imaging in perianal Crohn's disease. *Dtsch Med Wochenschr* 1993; 118: 1791-6.
853. Skorpen J, Malterud K. What did the doctor say- what did the patient hear? Operational knowledge in clinical communication. *Fam Pract.* 1997; 14: 382-6.
854. Slors JF, Ponson AE, Taat CW, Bosma A. Risk of residual rectal mucosa after proctocolectomy and ileal pouch-anal reconstruction with the double-stapling technique.

- Postoperative endoscopic follow-up study. *Dis Colon Rectum*. 1995; 38: 207-10.
855. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. *Inflamm Bowel Dis* 2005; 11: 707-12.
  856. Solomon MJ, McLeod RS, O'Connor BI, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. *Can J Gastroenterol* 1993; 7: 571-3.
  857. Solvig J, Ekberg O, Lindgren S, Florén C-H, Nilsson P. Ultrasound examination of the small bowel: comparison with enteroclysis in patients with Crohn disease. *Abdom Imaging* 1995; 20: 323-6.
  858. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn's disease. *Br Med J (Clin Res Ed)* 1984; 289: 954-6.
  859. Sonoda T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. *Dis.Colon Rectum* 2002, 45, 1622-28.
  860. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. *Indian J Gastroenterol* 2000; 19: 14-6.
  861. Soon SY, Ansari A, Yaneza M, Raouf S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2004; 16: 921-6.
  862. Staa TP van, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. *Gastroenterol* 2003; 125: 1591-7.
  863. Ståhlberg D, Veress B, Måre K, et al. Leucocyte migration in acute colonic inflammatory bowel disease: comparison of histological assessment and Tc-99mHMPAO labeled leucocyte scan. *Am J Gastroenterol* 1997; 92: 283-8.
  864. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR. European trial of ciclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. *Gastroenterol* 1995; 109: 774-82.
  865. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. *Gut*. 2006; 55 Suppl 1: 11-15.
  866. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. *J Rheumatol* 2003; 30: 518-22.
  867. Steger GG, Mader RM, Vogelsang H, Schofl R, Lochs H, Ferenci P. Folate absorption in Crohn's disease. *Digestion*. 1994; 55: 234-8.
  868. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2003; 4: CD000301.
  869. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. *Ann Int Med*, 1992; 116: 609-14.
  870. Stevenson M, Lloyd JM, De NE, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. *Health Technol Assess* 2005; 9 (22): 1-160.

871. Stewenius J, Adnerhill I, Anderson H, Ekelund GR, Floren CH, Fork FT, et al. Incidence of Colorectal cancer and all cause mortality in non-selected patients with Ulcerative Colitis and indeterminate colitis in Malmo, Sweden *Int J Colorectal Dis* 1995; 10: 117-22.
872. Stockdale AC, Williams B, Pennington CR. The role of the gastroenterologist in the provision of artificial nutrition support. *Aliment Pharmacol Ther* 1998; 12: 367-72.
873. Stokes MA, Hill GL. Total energy expenditure in patients with Crohn's disease: measurement by the combined body scan technique. *JPEN J Parenter Enteral Nutr*. 1993; 17: 3-7.
874. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. *Inflamm Bowel Dis* 2003; 9: 104-15.
875. Stratton RJ, Green CJ, Elia M. Consequences of disease related malnutrition. In: Stratton RJ, Green CJ, Elia M, editors. *Disease related malnutrition*. 1 ed. Cambridge: CABI Publishing; 2003. p. 113-55.
876. Sturniolo GC, Di Leo V, Ferronato A, D'Odorico A, D'Inca R. Zinc supplementation tightens "leaky gut" in Crohn's disease. *Inflamm Bowel Dis*. 2001; 7: 94-8.
877. Sturniolo GC, Mestriner C, Lecis PE, D'Odorico A, Venturi C, Irato P, Cecchetto A, Tropea A, Longo G, D'Inca R. Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. *Scand J Gastroenterol* 1998; 33: 644-9.
878. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. *Gastroenterol Clin North Am* 2002; 31: 307-27.
879. Sudan D, DiBaise J, Torres C, Thompson J, Raynor S, Gilroy R, Horslen S, Grant W, Botha J, Langnas A. A multidisciplinary approach to the treatment of intestinal failure. *J Gastrointest Surg* 2005; 9: 165-77.
880. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. *Arch Ophthalmol* 2005; 123: 903-12.
881. Summers RW, Switz DM, Sessions JT, Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterol* 1979; 77: 847-69.
882. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2006 9; : CD 000543. Update of: *Cochrane Database Syst Rev*. 2003; : CD000543.
883. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. *Gastroenterol* 1990; 98: 1123-8.
884. Sutphen JL, Cooper PH, Mackel SE, Nelson DL. Metastatic cutaneous Crohn's disease. *Gastroenterol* 1984; 86 : 941-4.
885. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J. Identification of a bacterial sequence associated with Crohn's disease. *Gastroenterol* 2000; 119: 23-31.
886. Svanoni F, Bonassi U, Bagnolo F, Caporuscio S. Effectiveness of ciclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC). *Gastroenterol* 1998; 114: A1096.
887. Tabet J, Hong D, Kim CW, et al. Laparoscopic versus open bowel resection for Crohn's disease. *Can J Gastroenterol* 2001; 15: 237-42.

888. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2006; 4: 196-202.
889. Talbot T, Jewell L, Schloss E, Yakimets W, Thomson AB. Cheilitis antedating Crohn's disease: case report and literature update of oral lesions. *J Clin Gastroenterol* 1984; 6: 349-54.
890. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. *Hepatol* 2004; 40: 39-45.
891. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn's disease: a meta-analysis. *Dis Colon Rectum*. 2007; 50: 576-85.
892. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997; 337: 1029-35.
893. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterol* 2005; 128: 2020-8.
894. Tarján Z, Tóth G, Györke T, Mester A, Karlinger K, Makó E. Ultrasound in Crohn's disease of the small bowel. *Eur J Radiol* 2000; 35: 176-82.
895. Tavela VF. Review article: Skin complications associated with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics, Supplement* 2004; 20: 50-53.
896. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. *Surgery* 2003; 134: 565-72; discussion 572-3.
897. Tekkis PP, Fazio VW, Lavery IC, Remzi FH, Senagore AJ, Wu JS, Strong SA, Poloneicki JD, Hull TL, Church JM. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. *Ann Surg*. 2005; 241: 262-8.
898. Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. *Scand J Gastroenterol* 2005; 40: 1205-13.
899. Tersigni R, Alessandrini L, Barreca M, Piovanello P, Prantera C. Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection? *HepatoGastroenterol* 2003; 50: 1422-5.
900. Thabane M, Newman JR, Irvine EJ, Anand A, Steinhart AH and Marshall JK. Rectal 5ASA to maintain remission of distal ulcerative colitis: a Cochrane collaboration metaanalysis. *Gastroenterol* 2005; 128 (Suppl.2): A311-2.
901. Thakur A, Yang I, Lin A, Buchmiller-Crair TF, Onkalsrud EW. Management of ovarian cysts in women undergoing restorative proctocolectomy for ulcerative colitis. *American Surgeon* 2003; 69: 339-42.
902. Thiru, Y, Bateman, D. N, and Coulthard, M. G. Successful breast feeding while mother was taking cyclosporine [letter]. *BMJ* 1997; 315: 463.



903. Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. *Gastroenterology*. 2001; 121: 275-81.
904. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. *N Engl J Med* 1998; 339: 370-4.
905. Thomson AB, Brust R, Ali MA, Mant MJ, Valberg LS. Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin: *Am J Dig Dis* 1978; 23: 705-9.
906. Tiainen J, Matikainen M, Hiltunen KM. Ileal J-pouch-anal anastomosis, sexual dysfunction, and fertility. *Scand J Gastroenterol* 1999; 34: 185-8.
907. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. *Gastroenterol*. 2000; 119: 15-22.
908. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. *Gastroenterol*. 2002; 123: 450-60.
909. Tibble JA, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. *Gut* 2000; 47: 506-13.
910. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. *Dis Colon Rectum* 2000; 43: 911-9.
911. Tilney HS, Constantinides VA, Heriot AG, Nicolaou M, Athanasiou T, Ziprin P, Darzi AW, Tekkis PP. Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis. *Surg Endosc* 2006; 20: 1036-44.
912. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study group. *Le Gastroenterology* 1998; 114: 1143-50.
913. Tirpitz C von, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. *Eur J Gastroenterol Hepatol* 2000; 12: 19-24.
914. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. *Am J Gastroenterol* 2007; 102: 107-114.
915. Tjandra JJ, Fazio VW, Milsom JW, Lavery IC, Oakley JR, Fabre JM. Omission of temporary diversion in restorative proctocolectomy--is it safe? *Dis Colon Rectum*. 1993 ; 36: 1007-14.
916. Tjandra JJ, Hughes LE. Parastomal pyoderma gangrenosum in inflammatory bowel disease. *Dis Colon Rectum* 1994; 37: 938-942.
917. Tobin MV, Logan RF, Langman MJ, et al. Cigarette smoking and inflammatory bowel disease. *Gastroenterol* 1987; 93: 316-21.
918. Tonelli F, Fedi M, Paroli GM, Fazi M. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. *Dis Colon Rectum* 2004; 47: 494-501.
919. Tonelli F, Paroli GM. Colorectal Crohn's disease: indications to surgical treatment. *Ann Ital Chir* 2003; 74: 665-72.
920. Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. *Gut*. 1996; 38: 905-10.

921. Travis SPL, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G et al, for the European Crohn's and Colitis Organisation (ECCO). European evidenced based consensus on the diagnosis and management of Crohn's disease : current management. *GUT* 2006; 55: 16-35.
922. Travis SPL. Review article: insurance risks for patients with ulcerative colitis or Crohn's disease. *Aliment Pharmacol Ther* 1997; 11: 51-9.
923. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. *Am J Gastroenterol* 2002; 97: 1748-54.
924. Tremaine WJ. Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD. *Inflamm Bowel Dis* 1998; 4: 68-69.
925. Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, Keniry A, Nimmo ER, Drummond H, Onnie CM, Prescott NJ, Sanderson J, Bredin F, Berzuini C, Forbes A, Lewis CM, Cardon L, Deloukas P, Jewell D, Mathew CG, Parkes M, Satsangi J. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. *Gastroenterol* 2007; 132: 1657-64.
926. Triester, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. *Am J Gastroenterol* 2006; 101: 954-64.
927. Tromm A, May D, Almus E, et al. Cutaneous manifestations in inflammatory bowel disease. *Z Gastroenterol* 2001; 39: 137-144.
928. Tromm A, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J, Stolte M. The probiotic *E. coli* strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. *Z Gastroenterol* 2004; 42: 365-9.
929. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J*. 1955; 2: 1041-8.
930. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Ann Int Med* 2001; 134: 89-95.
931. Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn WJ, Faubion WA. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis* 2006; 12: 1093-1100.
932. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. *Clin Gastroenterol Hepatol* 2007; 5: 103-10.
933. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. *Ann N Y Acad Sci* 2005; 1051: 166-73.
934. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. *Gut* 1988; 29: 990-6.
935. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. *Gastro* 2003; 125: 1311-9.

936. Umschaden HW, Szolar D, Gasser J, Umschaden M, Haselbach H. Small-bowel disease: comparison of MR enteroclysis images with conventional enteroclysis and surgical findings. *Radiology* 2000; 215: 717-25.
937. Vallis TM, Leddin D. What makes Crohn's disease patients difficult to manage? The role of psychosocial factors. *J Clin Psychol Med Settings* 2004; 11: 325-32.
938. Vasiliauskas E, Dubinsky M, Barry M, Targan S. High Serum Levels of Infliximab Detected in the Newborn of a Mother Receiving Infliximab During Pregnancy [poster]. *Gastroenterol* 2005; 128 (suppl 2): A26.
939. Vasiliauskas EA, Kam LY, Breu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. *Gastroenterol* 1999; 117: 1278-87.
940. Vavassori P, Borgiani P, D'Apice MR, De Negris F, Del Vecchio Blanco G, Monteleone I, et al. 3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. *Dig Liver Dis* 2002; 34: 153.
941. Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. *Gastroenterol* 2006; 130: 1941-49.
942. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. *Am J Gastroenterol* 2005; 100: 1345-53.
943. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol* 1996; 23: 29-34.
944. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: more of the same or progress? *Gastroenterol* 1994; 107: 1196-9.
945. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Briggidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Alliment Pharmacol Ther*, 1999; 13: 1103-8.
946. Verma S, Brown S, Kirkwood B and Gaffer MH. Polymeric versus elemental diet as primary therapy in active Crohn's disease: a randomized, double-blind trial. *Am J Gastroenterol*, 2000; 95: 735-9.
947. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. *Am J Gastroenterol* 2002; 97: 2357-63.
948. Vermeire S, Noman M, Assche G van, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut*. 2007 Sep; 56: 1226-31. Epub 2007 17.
949. Vermeire S, Assche G van, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut*. 2006; 55: 426-31.
950. Vermeire S, Assche van, G, Rutgeerts, P. C-Reactive Protein as a Marker for Inflammatory Bowel Disease a review. *Inflamm Bowel Dis* 2004; 10: 661-5.
951. Verzijl JM, Van Dijk A. Plaatsbepaling van orale mesalazinepreparaten bij colitis ulcerosa en ziekte van Crohn. *Pharm Weekbl* 1991; 126: 232-38.

952. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. *Br Med J* 1986; 292: 526.
953. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000; 46: 176-81.
954. Vilien M, Dahlerup JF, Munck LK, Norregaard P, Gronbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. *Aliment Pharmacol Ther.* 2004; 19: 1147-52.
955. Vitellas KM, El-Dieb A, Vaswani KK, et al. MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. *AJR Am J Roentgenol* 2002; 179: 399-407.
956. Vlam K de, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. *J Reumatol.* 2000; 27: 2860-5.
957. Vos VM de. Review article: Joint involvement in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics, Supplement* 2004; 20: 36-42.
958. Vrij AA, Jansen JM, Schoon EJ, de Bruïne A, Hemker HC, Stockbrugger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. *Scand J Gastroenterol Suppl* 2001; (234): 41-47.
959. Vrij AA, Rijken J, Wersch JW van, Stockbrugger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. *Pathophysiol Haemost Thromb* 2003; 33: 75-83.
960. Waal RI van der, Schulten EA, Meij EH van der, Scheur MR van de, Starink TM, Waal I van der. Cheilitis granulomatosa: overview of 13 patients with long-term follow-up-results of management. *Int J Dermatol.* 2002; 41: 225-9.
961. Wagtmans MJ, van Hogezaand RA, Griffioen G, Verspaget HW, Lamers CB. Crohn's disease of the upper gastrointestinal tract. *Neth J Med* 1997; 50: S2-7.
962. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezaand RA. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. *Am J Gastroenterol* 1997; 92: 1467-71.
963. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. *Lancet* 1989; 2 (8671): 1057-1062.
964. Waters B.M, Jensen L, Fedorak R.N. Effect of formal education for patient with inflammatory bowel disease: A randomise controlled trial. *Ca J Gastroenterol* 2005; 19: 235-244.
965. Weersma RK, van Dullemen HM, Kleibeuker JH, Ploeg RJ, Dijkstra G. Behandeling van ernstige colitis ulcerosa. *Ned Tijdschr Geneesk.* 2006; 150: 12-7.
966. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet* 1980; 32: 651-62.
967. Weiss G, Goodnough LT Anemia of chronic disease. *N Engl J Med* 2005; 352: 1011-23.
968. Wells AD, et al. Natural history of indeterminate colitis. *Br J Surg* 1991; 78: 179-81.

969. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. *Inflamm Bowel Dis*. 2006; 12: 123-30.
970. West RL, Dwarkasing S, Felt-Bersma RJ, Schouten WR, Hop WC, Hussain SM, Kuipers EJ. Hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging in evaluating perianal fistulas: agreement and patient preference. *Eur J Gastroenterol Hepatol* 2004; 16: 1319-24.
971. West RL, Zimmerman DDE, Dwarkasing S, et al. Prospective comparison of hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging of perianal fistulas. *Dis Colon rectum* 2003; 46: 1407-15.
972. Weston LA, Roberts PL, Schoetz DJ Jr, Collier JA, Murray JJ, Rusin LC. Ileocolic resection for acute presentation of Crohn's disease of the ileum. *Dis Colon Rectum*. 1996; 39: 841-6.
973. Wheeler JM, Banerjee A, Ahuja N, Jewell DP, Mortensen NJ. Long-term function after restorative proctocolectomy. *Dis Colon Rectum*. 2005; 48: 946-51.
974. Whitehead WE. Behavioral medicine approaches to gastrointestinal disorders. *Journal of Consulting and Clinical Psychology* 1992; 60: 605-12.
975. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterol* 2003; 124: 544-60.
976. Winter HS. Treatment of pyoderma gangrenosum, erythema nodosum, and aphthous ulcerations. *Inflamm Bowel Dis* 1998; 4: 71.
977. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. *Gastroenterol* 2003; 125: 1576-82.
978. Wit NJ de, Witteman BJM. Diarrhea. *Huisarts Wet* 2002; 45: 478-82.
979. Wold PB, Fletcher JG, Johnson CD, Sandborn WJ. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy. Feasibility study. *Radiology* 2003; 229: 275-81.
980. Wolfe SP. 'Prevention programmes'--a dietetic minefield. *Eur J Clin Nutr* 1995; 49 Suppl 1: S92-9.
981. Wolters FL, Russel MG, Sijbrandij J, et al. The European Collaborative Study Group on Inflammatory Bowel Disease. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. *Gut* 2006; 55: 510-8.
982. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. *Gut* 2006; 55: 1124-30.
983. Woolfson, K, Cohen, Z, and McLeod, R. S. Crohn's disease and pregnancy. *Dis Colon Rectum* 1990; 33: 869-873.
984. Wu JS, Birnbaum EH, Kodner IJ, et al. Laparoscopic-assisted ileocolic resections in patients with Crohn's disease: are abscesses, phlegmons, or recurrent disease contraindications? *Surgery* 1997; 122: 682-8.
985. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. *J Gastroenterol* 2004; 39: 441-8.

986. Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S, Ido K, Sugano K. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001; 53: 216-20.
987. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. *Dis Colon Rectum*. 2000; 43: 1141-5.
988. Yamamoto T, Bain I, Connolly A, et al. Gastroduodenal fistulas in Crohn's disease: clinical features and management. *Dis Colon Rectum* 1998; 41: 1287-92.
989. Yamamoto T, Bain IM, Mylonakis E, Allan RN, Keighley MR. Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease. *Scand J Gastroenterol* 1999; 34: 708-13.
990. Yamamoto T, Keighley MR. Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis. *Scand J Gastroenterol* 1999; 34: 1212-5.
991. Yamamoto T, Mylonakis E, Keighley MR. Omentoplasty for persistent perineal sinus after proctectomy for Crohn's disease. *Am J Surg*. 2001; 181: 265-7.
992. Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. *Histopathology* 2006; 48: 116-132.
993. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann Intern Med* 1997; 126: 608-14.
994. Young-Fadok TM, HallLong K, McConnell EJ, Gomez Rey G, Cabanela RL. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. *Surg Endosc* 2001; 15: 450-4.
995. Young-Fadok TM, Wolff B, Meagher A, et al. Surgical management of ileosigmoid fistulas in Crohn's disease. *Dis Colon Rectum* 1997; 40: 558-61.
996. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2007; 24: CD000542. Update of: *Cochrane Database Syst Rev*. 2001: CD000542.
997. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. *Am J Gastroenterol* 2004; 99: 2235-41.
998. Zurita VF, Rawls DE, Dyck WP. Nutritional support in inflammatory bowel disease. *Dig Dis*. 1995; 13: 92-107.